<?xml version="1.0" encoding="UTF-8"?>
<COCHRANE_REVIEW TYPE="INTERVENTION" REVMAN_VERSION="5" ID="000000000000000000" VERSION_NO="7.0" STAGE="R" STATUS="A">
<COVER_SHEET>
<TITLE>Anti-vascular endothelial growth factor for neovascular age-related macular degeneration [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2019, Issue 3".]</TITLE>
<CONTACT>
<PERSON ID="z1310081512082934169030929157306" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sharon</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Solomon</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Associate Professor of Ophthalmology</POSITION>
<EMAIL_1>ssolomon1@jhmi.edu</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Wilmer Eye Institute</DEPARTMENT>
<ORGANISATION>Johns Hopkins University School of Medicine</ORGANISATION>
<ADDRESS_1>600 North Wolfe Street</ADDRESS_1>
<ADDRESS_2>Maumenee 740</ADDRESS_2>
<CITY>Baltimore</CITY>
<ZIP>21287</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>410-614-6908</PHONE_1>
</ADDRESS>
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="z1310081512082934169030929157306" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sharon</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Solomon</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Associate Professor of Ophthalmology</POSITION>
<EMAIL_1>ssolomon1@jhmi.edu</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Wilmer Eye Institute</DEPARTMENT>
<ORGANISATION>Johns Hopkins University School of Medicine</ORGANISATION>
<ADDRESS_1>600 North Wolfe Street</ADDRESS_1>
<ADDRESS_2>Maumenee 740</ADDRESS_2>
<CITY>Baltimore</CITY>
<ZIP>21287</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>410-614-6908</PHONE_1>
</ADDRESS>
</PERSON>
<PERSON ID="9501BF6E82E26AA20020E746E9A900D1" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Kristina</FIRST_NAME>
<LAST_NAME>Lindsley</LAST_NAME>
<POSITION>Project Director, CEV US Project (Satellite)</POSITION>
<EMAIL_1>K.B.Lindsley@umcutrecht.nl</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Johns Hopkins Bloomberg School of Public Health</ORGANISATION>
<ADDRESS_1>615 North Wolfe Street, Mail Room E6132</ADDRESS_1>
<CITY>Baltimore</CITY>
<ZIP>21205</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 410 502 8986</PHONE_1>
</ADDRESS>
</PERSON>
<PERSON ID="DC7E132D82E26AA2001B9B03E7E641B3" ROLE="AUTHOR">
<FIRST_NAME>Satyanarayana</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Vedula</LAST_NAME>
<EMAIL_1>vedula@jhu.edu</EMAIL_1>
<ADDRESS>
<ORGANISATION>Johns Hopkins University</ORGANISATION>
<ADDRESS_1>3400 N. Charles Street</ADDRESS_1>
<CITY>Baltimore</CITY>
<ZIP>21218</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
</ADDRESS>
</PERSON>
<PERSON ID="11254" ROLE="AUTHOR">
<FIRST_NAME>Magdalena</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Krzystolik</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<EMAIL_1>Magdalena_Krzystolik@meei.harvard.edu</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Department of Ophthalmology, Retina Service</DEPARTMENT>
<ORGANISATION>Mass Eye and Ear Infirmary</ORGANISATION>
<ADDRESS_1>1 Randall Square, Suite 203</ADDRESS_1>
<CITY>Providence</CITY>
<ZIP>02904</ZIP>
<REGION>Rhode Island</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 401 453 4600</PHONE_1>
<FAX_1>+1 401 453 0077</FAX_1>
</ADDRESS>
</PERSON>
<PERSON ID="EBE4D98A82E26AA2001B9B0304FBCF48" ROLE="AUTHOR">
<FIRST_NAME>Barbara</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Hawkins</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<EMAIL_1>bhawkins@jhmi.edu</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Wilmer Eye Institute</DEPARTMENT>
<ORGANISATION>Johns Hopkins University School of Medicine</ORGANISATION>
<ADDRESS_1>550 North Broadway, 9th floor</ADDRESS_1>
<CITY>Baltimore</CITY>
<ZIP>21205-2010</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 410 955 8318</PHONE_1>
<FAX_1>+1 410 955 0569</FAX_1>
</ADDRESS>
</PERSON>
</CREATORS>
<DATES>
<UP_TO_DATE>
<DATE DAY="" MONTH="" YEAR="" />
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="" MONTH="" YEAR="" />
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR="" />
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR="" />
<REVIEW_PUBLISHED ISSUE="" YEAR="" />
<LAST_CITATION_ISSUE ISSUE="" YEAR="" />
</DATES>
<WHATS_NEW />
<HISTORY />
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES />
<EXTERNAL_SOURCES />
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO" />
<KEYWORDS />
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Anti-vascular endothelial growth factor for neovascular age-related macular degeneration</TITLE>
<SUMMARY_BODY>
<P><B>What is the aim of this review?</B><BR />
The aim of this Cochrane review was to compare treatment with anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (wet AMD). This review focuses on two questions: (1) whether using anti-VEGF agents is better than not using them, and (2) which anti-VEGF agent works best.</P>
<P><B>Key messages</B><BR />
Anti-VEGF agents were better than no anti-VEGF agents or other types of treatment for patients with wet AMD. When studies compared anti-VEGF agents, researchers found that ranibizumab and bevacizumab were similar in terms of vision-related outcomes and numbers of adverse events among participants followed for at least one year. The major difference was cost, as bevacizumab was cheaper.</P>
<P><B>What was studied in this review?</B><BR />
Wet AMD is a common cause of severe vision loss among people 55 years of age and older. The macula, located in the central retina in the back of the eye, is important for vision. Wet AMD occurs when abnormal growth of blood vessels in the back of the eye damages the macula. Wet AMD causes blurriness, darkness, or distortion in the center of the field of vision, thus reducing the individual's ability to read, drive, and see faces.</P>
<P>Injection into the eye of medicines like pegaptanib, ranibizumab, and bevacizumab can help block abnormal growth of blood vessels in the back of the eye. These drugs are known as anti-VEGF agents. We conducted this review to compare benefits and risks of treatment with anti-VEGF agents versus treatment without anti-VEGF agents and to compare different types of anti-VEGF agents.</P>
<P><B>What are the main results of the review?</B><BR />
We found 16 studies that enrolled a total of 6347 people with wet AMD. Six studies compared anti-VEGF agents against no anti-VEGF agent, and ten studies compared bevacizumab versus ranibizumab. Drug companies conducted or sponsored four of the studies. Investigators conducted the 16 studies at various centers on five continents (North and South America, Europe, Asia, and Australia); they treated people and provided follow-up for at least one year.</P>
<P>After one year, more people treated with any of the three anti-VEGF agents (pegaptanib, ranibizumab, or bevacizumab) had improved vision, fewer had vision loss, and fewer were legally blind in the study eye when compared with people who did not receive anti-VEGF agents. People treated with anti-VEGF agents also showed structural improvements in the eye, which doctors use to monitor the disease and determine the need for more treatment. People who did not receive anti-VEGF agents did not show the same kind of improvement.</P>
<P>Treatment with ranibizumab or bevacizumab yielded larger improvements in vision compared with treatment with pegaptanib in trials comparing anti-VEGF treatment against treatment not using anti-VEGF agents. Comparison of bevacizumab versus ranibizumab revealed no major differences with respect to any vision-related outcomes. The major difference between the two agents was cost; bevacizumab was cheaper.</P>
<P>Inflammation and increased pressure in the eye were the most common unwanted effects caused by anti-VEGF agents. Investigators reported endophthalmitis (infection in the inner part of the eye, which can cause blindness) in less than 1% of anti-VEGF-treated eyes and observed no cases among those not treated with anti-VEGF agents. The occurrence of serious side effects, such as high blood pressure and internal bleeding, was low and was similar between anti-VEGF-treated groups and groups that did not receive anti-VEGFs. The number of total side effects was very small, so it is impossible to tell which drug may have caused the most harmful effects.</P>
<P><B>How up-to-date is this review?</B><BR />
Cochrane researchers searched for studies that had been published up to January 31, 2018.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P />
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P />
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P />
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P />
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P />
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P />
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P />
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P />
<CONDITION>
<P />
</CONDITION>
<INTERVENTION>
<P />
</INTERVENTION>
<THEORY>
<P />
</THEORY>
<IMPORTANCE>
<P />
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P />
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P />
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P />
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P />
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P />
<CRIT_OUTCOMES_PRIMARY>
<P />
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY>
<P />
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P />
<ELECTRONIC_SEARCHES>
<P />
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES>
<P />
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P />
<STUDY_SELECTION>
<P />
</STUDY_SELECTION>
<DATA_EXTRACTION>
<P />
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT>
<P />
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES>
<P />
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS>
<P />
</UNIT_OF_ANALYSIS>
<MISSING_DATA>
<P />
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT>
<P />
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT>
<P />
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS>
<P />
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS>
<P />
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS>
<P />
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P />
<SEARCH_RESULTS>
<P />
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR>
<P />
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR>
<P />
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P />
<ALLOCATION>
<P />
</ALLOCATION>
<BLINDING>
<P />
</BLINDING>
<EXCLUSIONS>
<P />
</EXCLUSIONS>
<SELECTIVE_REPORTING>
<P />
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES>
<P />
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P />
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P />
<SUMMARY_OF_RESULTS>
<P />
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS>
<P />
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE>
<P />
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES>
<P />
</POTENTIAL_BIASES>
<AGREEMENT>
<P />
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P />
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P />
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P />
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P />
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P />
</CONTRIBUTIONS>
<PRO_REV_DIFF>
<P />
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P />
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-ABC-2010" NAME="ABC 2010" YEAR="2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-ANCHOR-2006" NAME="ANCHOR 2006" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswas-2011" NAME="Biswas 2011" YEAR="2011">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BRAMD-2016" NAME="BRAMD 2016" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-CATT-2011" NAME="CATT 2011" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-GEFAL-2013" NAME="GEFAL 2013" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-IVAN-2013" NAME="IVAN 2013" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-LUCAS-2015" NAME="LUCAS 2015" YEAR="2015">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MANTA-2013" NAME="MANTA 2013" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MARINA-2006" NAME="MARINA 2006" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PIER-2008" NAME="PIER 2008" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sacu-2009" NAME="Sacu 2009" YEAR="2009">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-SAVE_x002d_AMD-2017" NAME="SAVE-AMD 2017" YEAR="2016">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scholler-2014" NAME="Scholler 2014" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Subramanian-2010" NAME="Subramanian 2010" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-VISION-2004" NAME="VISION 2004" YEAR="">
<IDENTIFIERS />
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES />
<AWAITING_STUDIES />
<ONGOING_STUDIES />
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES />
<OTHER_VERSIONS_REFERENCES />
<PENDING_REFERENCES />
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-ABC-2010">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-ANCHOR-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Biswas-2011">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-BRAMD-2016">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CATT-2011">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-GEFAL-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-IVAN-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-LUCAS-2015">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MANTA-2013">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MARINA-2006">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PIER-2008">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sacu-2009">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SAVE_x002d_AMD-2017">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scholler-2014">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Subramanian-2010">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-VISION-2004">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS />
<SOF_TABLES />
<ADDITIONAL_TABLES />
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Anti-VEGF treatment versus control</NAME>
<DICH_OUTCOME CHI2="12.418254038885726" CI_END="7.5502683402951725" CI_START="2.3199426971541897" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="4.185234748209743" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="35" I2="59.73669096844597" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8779623869455484" LOG_CI_START="0.36547725790078" LOG_EFFECT_SIZE="0.6217198224231643" METHOD="MH" NO="1" P_CHI2="0.02948511781837615" P_Q="0.380841390403012" P_Z="1.98005793201935E-6" Q="1.9307450017798837" RANDOM="YES" SCALE="59.06" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2956679196531256" TOTALS="YES" TOTAL_1="1847" TOTAL_2="820" WEIGHT="99.99999999999999" Z="4.755449051547378">
<NAME>Gain of 15 or more letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.5197151958682396" CI_START="1.2257802951164471" DF="0" EFFECT_SIZE="2.826966292134831" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="6" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.8142286246330873" LOG_CI_START="0.08841263562354962" LOG_EFFECT_SIZE="0.45132063012831847" NO="1" P_CHI2="1.0" P_Z="0.014791024086888578" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="18.980975292142915" Z="2.437455757177604">
<NAME>Pegaptanib vs control</NAME>
<DICH_DATA CI_END="6.5197151958682396" CI_START="1.2257802951164471" EFFECT_SIZE="2.8269662921348315" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="6" LOG_CI_END="0.8142286246330873" LOG_CI_START="0.08841263562354962" LOG_EFFECT_SIZE="0.4513206301283185" ORDER="219" O_E="0.0" SE="0.42634790479129275" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" VAR="0.18177253591992523" WEIGHT="18.980975292142915">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.756320596060814" CI_END="9.665985773465191" CI_START="1.5891187040999761" DF="2" EFFECT_SIZE="3.9192344643026664" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="26" I2="79.50046864175913" ID="CMP-001.01.02" LOG_CI_END="0.9852461516025606" LOG_CI_START="0.20115633937862784" LOG_EFFECT_SIZE="0.5932012454905942" NO="2" P_CHI2="0.007611015006839472" P_Z="0.003020813337871824" STUDIES="3" TAU2="0.5014369091491059" TOTAL_1="878" TOTAL_2="444" WEIGHT="63.40879370589276" Z="2.9656119965344456">
<NAME>Ranibizumab vs control</NAME>
<DICH_DATA CI_END="13.53672142008375" CI_START="3.40707688056536" EFFECT_SIZE="6.791218637992832" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="8" LOG_CI_END="1.1315134914110156" LOG_CI_START="0.5323819335175664" LOG_EFFECT_SIZE="0.8319477124642909" ORDER="62" O_E="0.0" SE="0.3519328428556547" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.12385672588046294" WEIGHT="21.601318509369857">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.258061176035982" CI_START="3.2894736767707475" EFFECT_SIZE="5.808926080892608" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="12" LOG_CI_END="1.0110652847410069" LOG_CI_START="0.5171264154090056" LOG_EFFECT_SIZE="0.7640958500750062" ORDER="63" O_E="0.0" SE="0.29014213688245377" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.08418245959471654" WEIGHT="23.85751334155872">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.1901946491195083" CI_START="0.5310961991559369" EFFECT_SIZE="1.3016528925619835" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.5038171822607901" LOG_CI_START="-0.2748268066424516" LOG_EFFECT_SIZE="0.11449518780916923" ORDER="64" O_E="0.0" SE="0.4573793334316715" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.2091958546504001" WEIGHT="17.949961854964187">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6086330763685283" CI_END="24.981879063362552" CI_START="2.4374053237311664" DF="1" EFFECT_SIZE="7.803266304942313" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="1.3976251016184875" LOG_CI_START="0.38692775537378526" LOG_EFFECT_SIZE="0.8922764284961364" NO="3" P_CHI2="0.43530312568445695" P_Z="5.388936068284262E-4" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="80" WEIGHT="17.61023100196431" Z="3.460639667461921">
<NAME>Bevacizumab vs control</NAME>
<DICH_DATA CI_END="43.64213116155179" CI_START="2.604556636936292" EFFECT_SIZE="10.661538461538461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.6399059501908928" LOG_CI_START="0.41573380574700947" LOG_EFFECT_SIZE="1.0278198779689511" ORDER="220" O_E="0.0" SE="0.7190847773961824" STUDY_ID="STD-ABC-2010" TOTAL_1="65" TOTAL_2="66" VAR="0.5170829170829172" WEIGHT="11.15013984740405">
<FOOTNOTE>Control group in the ABC study received standard therapy including pegaptanib injections, verteporfin PDT, or sham injection</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="31.455858516002134" CI_START="0.5086492868048897" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4977015427613454" LOG_CI_START="-0.2935815601054206" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="221" O_E="0.0" SE="1.0522085616183026" STUDY_ID="STD-Sacu-2009" TOTAL_1="14" TOTAL_2="14" VAR="1.1071428571428572" WEIGHT="6.460091154560259">
<FOOTNOTE>Control group in the Sacu 2009 study received verteporfin photodynamic therapy plus same day 4 mg intravitreal triamcinolone acetonide</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8408175032418383" CI_END="9.842508676538252" CI_START="3.3782302518044443" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="5.766303891118577" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="21" I2="29.59773031116317" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9931058063092089" LOG_CI_START="0.5286892466797098" LOG_EFFECT_SIZE="0.7608975264944593" METHOD="MH" NO="2" P_CHI2="0.2416155616640715" P_Q="1.0" P_Z="1.341526534441884E-10" Q="0.0" RANDOM="YES" SCALE="27.28" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06752459482432603" TOTALS="YES" TOTAL_1="878" TOTAL_2="444" WEIGHT="100.00000000000001" Z="6.422388336214808">
<NAME>Gain of 15 or more letters visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.456824238139344" CI_START="3.1209944553589772" EFFECT_SIZE="5.979689366786141" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="9" LOG_CI_END="1.0590642505293313" LOG_CI_START="0.49429299711482344" LOG_EFFECT_SIZE="0.7766786238220774" ORDER="62" O_E="0.0" SE="0.33174942991847417" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.11005768425123262" WEIGHT="41.90742461647577">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="15.131530388453315" CI_START="4.078560758587808" EFFECT_SIZE="7.855880985588098" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="9" LOG_CI_END="1.1798828543714235" LOG_CI_START="0.6105069364048258" LOG_EFFECT_SIZE="0.8951948953881247" ORDER="63" O_E="0.0" SE="0.33445423266982877" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.11185963375076394" WEIGHT="41.48645637743856">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.141581372901664" CI_START="0.7251287965312623" EFFECT_SIZE="2.4297520661157024" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.9107087678895086" LOG_CI_START="-0.13958484769809418" LOG_EFFECT_SIZE="0.3855619600957072" ORDER="64" O_E="0.0" SE="0.616947668833404" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.38062442607897157" WEIGHT="16.606119006085674">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.185673778940512" CI_END="1.5542524700225562" CI_START="1.2683109458663786" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4040211609407685" ESTIMABLE="YES" EVENTS_1="1508" EVENTS_2="491" I2="62.080056856967396" I2_Q="81.14373271906172" ID="CMP-001.03" LOG_CI_END="0.1915215662227985" LOG_CI_START="0.10322574054789752" LOG_EFFECT_SIZE="0.14737365338534797" METHOD="MH" NO="3" P_CHI2="0.0216995804422071" P_Q="0.004975276864211731" P_Z="6.041334447824656E-11" Q="10.606553090291582" RANDOM="YES" SCALE="2.49" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009216862659227094" TOTALS="YES" TOTAL_1="1847" TOTAL_2="820" WEIGHT="99.99999999999999" Z="6.54271140674047">
<NAME>Loss of fewer than 15 letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.387338700900039" CI_START="1.1102890471852216" DF="0" EFFECT_SIZE="1.24110715264456" ESTIMABLE="YES" EVENTS_1="612" EVENTS_2="164" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.14218250142991884" LOG_CI_START="0.045436055593859374" LOG_EFFECT_SIZE="0.09380927851188907" NO="1" P_CHI2="1.0" P_Z="1.4415915972633154E-4" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="21.61277410359997" Z="3.8009211751417187">
<NAME>Pegaptanib vs control</NAME>
<DICH_DATA CI_END="1.387338700900039" CI_START="1.1102890471852216" EFFECT_SIZE="1.24110715264456" ESTIMABLE="YES" EVENTS_1="612" EVENTS_2="164" LOG_CI_END="0.14218250142991884" LOG_CI_START="0.045436055593859374" LOG_EFFECT_SIZE="0.09380927851188907" ORDER="219" O_E="0.0" SE="0.05682934118673184" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" VAR="0.0032295740197179753" WEIGHT="21.61277410359997">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4306829971815267" CI_END="1.6445153187832486" CI_START="1.4145610218946025" DF="2" EFFECT_SIZE="1.5252105657447301" ESTIMABLE="YES" EVENTS_1="823" EVENTS_2="271" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.2160379233231115" LOG_CI_START="0.1506216869647858" LOG_EFFECT_SIZE="0.18332980514394862" NO="2" P_CHI2="0.4890251530546338" P_Z="4.48020608542283E-28" STUDIES="3" TAU2="0.0" TOTAL_1="878" TOTAL_2="444" WEIGHT="52.90798422048748" Z="10.985646236407284">
<NAME>Ranibizumab vs control</NAME>
<DICH_DATA CI_END="1.6788323475729479" CI_START="1.3081090744100354" EFFECT_SIZE="1.4819230169861306" ESTIMABLE="YES" EVENTS_1="266" EVENTS_2="92" LOG_CI_END="0.2250073285624999" LOG_CI_START="0.1166439583914521" LOG_EFFECT_SIZE="0.17082564347697599" ORDER="62" O_E="0.0" SE="0.0636531800458069" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.00405172732994391" WEIGHT="20.273595352357976">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6828820685442003" CI_START="1.3740352574419301" EFFECT_SIZE="1.5206377926043197" ESTIMABLE="YES" EVENTS_1="452" EVENTS_2="148" LOG_CI_END="0.2260536829544199" LOG_CI_START="0.13799787676721567" LOG_EFFECT_SIZE="0.18202577986081778" ORDER="63" O_E="0.0" SE="0.05172441643763419" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.002675415255813802" WEIGHT="22.619890508661705">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.2879670431835053" CI_START="1.3593015256308878" EFFECT_SIZE="1.7635297254065583" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="31" LOG_CI_END="0.3594497644100473" LOG_CI_START="0.13331580433554666" LOG_EFFECT_SIZE="0.24638278437279704" ORDER="64" O_E="0.0" SE="0.1328322075289172" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.01764439535700533" WEIGHT="10.014498359467796">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1496248548381762" CI_END="1.5035083363187023" CI_START="1.0895350309509484" DF="1" EFFECT_SIZE="1.2798925742991114" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="56" I2="13.015102640525093" ID="CMP-001.03.03" LOG_CI_END="0.17710584042268526" LOG_CI_START="0.037241198330886016" LOG_EFFECT_SIZE="0.10717351937678567" NO="3" P_CHI2="0.2836277397566873" P_Z="0.0026671159535083424" STUDIES="2" TAU2="0.001853289260362696" TOTAL_1="79" TOTAL_2="80" WEIGHT="25.479241675912533" Z="3.00370751225369">
<NAME>Bevacizumab vs control</NAME>
<DICH_DATA CI_END="1.6421353221148536" CI_START="1.128888074742274" EFFECT_SIZE="1.3615384615384616" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.2154089428115599" LOG_CI_START="0.0526508852983799" LOG_EFFECT_SIZE="0.13402991405496986" ORDER="220" O_E="0.0" SE="0.09560488864862024" STUDY_ID="STD-ABC-2010" TOTAL_1="65" TOTAL_2="66" VAR="0.009140294733515075" WEIGHT="14.653795170005763">
<FOOTNOTE>Control group in the ABC study received standard therapy including pegaptanib injections, verteporfin PDT, or sham injection</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4821175133930105" CI_START="0.907890223170981" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.17088263913240878" LOG_CI_START="-0.04196666067857192" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="221" O_E="0.0" SE="0.12502873232999673" STUDY_ID="STD-Sacu-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.015632183908045966" WEIGHT="10.82544650590677">
<FOOTNOTE>Control group in the Sacu 2009 study received verteporfin photodynamic therapy plus same day 4 mg intravitreal triamcinolone acetonide</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.023897561844622" CI_END="1.9751911003877904" CI_START="1.322281025932065" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6160933496034975" ESTIMABLE="YES" EVENTS_1="783" EVENTS_2="246" I2="77.83662783965414" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.29560912012902923" LOG_CI_START="0.12132376607333199" LOG_EFFECT_SIZE="0.20846644310118065" METHOD="MH" NO="4" P_CHI2="0.010977062326212206" P_Q="1.0" P_Z="2.749330023069885E-6" Q="0.0" RANDOM="YES" SCALE="3.03" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.022898096393300992" TOTALS="YES" TOTAL_1="878" TOTAL_2="444" WEIGHT="100.0" Z="4.688709761956343">
<NAME>Loss of fewer than 15 letters visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5502981398078464" CI_START="1.2082037468519848" EFFECT_SIZE="1.3686036757416304" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="94" LOG_CI_END="0.19041522592661916" LOG_CI_START="0.08214017821898838" LOG_EFFECT_SIZE="0.13627770207280374" ORDER="11" O_E="0.0" SE="0.06360129899359249" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.004045125233672348" WEIGHT="38.899808788971065">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.944053594972529" CI_START="1.5199430325129133" EFFECT_SIZE="1.7189679218967922" ESTIMABLE="YES" EVENTS_1="435" EVENTS_2="126" LOG_CI_END="0.2887082336766652" LOG_CI_START="0.18182731088626986" LOG_EFFECT_SIZE="0.2352677722814675" ORDER="12" O_E="0.0" SE="0.06278238311617879" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.003941627629746651" WEIGHT="39.04981170999101">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.64210300041771" CI_START="1.4280959470027776" EFFECT_SIZE="1.942466624284806" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="26" LOG_CI_END="0.42194974425545845" LOG_CI_START="0.15475738660965854" LOG_EFFECT_SIZE="0.2883535654325585" ORDER="13" O_E="0.0" SE="0.1569501135046442" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.024633338129120698" WEIGHT="22.050379501037913">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.225336616625588" CI_END="1.1886559223439797" CI_START="1.0575062937564441" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1211650721413102" ESTIMABLE="YES" EVENTS_1="1614" EVENTS_2="622" I2="73.27474353368817" I2_Q="79.48175835039093" ID="CMP-001.05" LOG_CI_END="0.07505615852701181" LOG_CI_START="0.02428296076155782" LOG_EFFECT_SIZE="0.04966955964428477" METHOD="MH" NO="5" P_CHI2="0.010567774220515913" P_Q="0.007644946446489387" P_Z="1.2570641522123267E-4" Q="9.747423946720627" RANDOM="YES" SCALE="1.53" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0025998020845978283" TOTALS="YES" TOTAL_1="1712" TOTAL_2="743" WEIGHT="100.0" Z="3.8347219523368063">
<NAME>Loss of fewer than 30 letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2253723247921318" CI_START="1.077251640777356" DF="0" EFFECT_SIZE="1.1489274770173648" ESTIMABLE="YES" EVENTS_1="798" EVENTS_2="231" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.08826806750418613" LOG_CI_START="0.032317164241035756" LOG_EFFECT_SIZE="0.06029261587261095" NO="1" P_CHI2="1.0" P_Z="2.3988798609259565E-5" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="24.171327720161457" Z="4.224108950957866">
<NAME>Pegaptanib vs control</NAME>
<DICH_DATA CI_END="1.2253723247921318" CI_START="1.077251640777356" EFFECT_SIZE="1.1489274770173648" ESTIMABLE="YES" EVENTS_1="798" EVENTS_2="231" LOG_CI_END="0.08826806750418613" LOG_CI_START="0.032317164241035756" LOG_EFFECT_SIZE="0.06029261587261095" ORDER="219" O_E="0.0" SE="0.03286583753821243" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" VAR="0.001080163277088173" WEIGHT="24.171327720161457">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.979112909680742E-6" CI_END="1.20267987679364" CI_START="1.108254141829393" DF="1" EFFECT_SIZE="1.154502037569192" ESTIMABLE="YES" EVENTS_1="752" EVENTS_2="328" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.08015004442774319" LOG_CI_START="0.04463936304404443" LOG_EFFECT_SIZE="0.06239470373589385" NO="2" P_CHI2="0.9984084037588494" P_Z="5.6748501998011785E-12" STUDIES="2" TAU2="0.0" TOTAL_1="757" TOTAL_2="381" WEIGHT="50.854653442690186" Z="6.887582405249855">
<NAME>Ranibizumab vs control</NAME>
<DICH_DATA CI_END="1.2318899814837707" CI_START="1.082086352877548" EFFECT_SIZE="1.1545611015490533" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="124" LOG_CI_END="0.09057192327642065" LOG_CI_START="0.03426191981101413" LOG_EFFECT_SIZE="0.062416921543717384" ORDER="62" O_E="0.0" SE="0.03307677477459239" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.0010940730294891118" WEIGHT="24.08030753853507">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2169090500176136" CI_START="1.0952214643627096" EFFECT_SIZE="1.154463040446304" ESTIMABLE="YES" EVENTS_1="473" EVENTS_2="204" LOG_CI_END="0.08525812091577241" LOG_CI_START="0.03950194659683936" LOG_EFFECT_SIZE="0.06238003375630591" ORDER="63" O_E="0.0" SE="0.026877403291657023" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="7.223948077023758E-4" WEIGHT="26.774345904155116">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0961485237682085" CI_START="0.9706677565317102" DF="0" EFFECT_SIZE="1.0315018315018316" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.03986940331150125" LOG_CI_START="-0.01292939645286405" LOG_EFFECT_SIZE="0.013470003429318611" NO="3" P_CHI2="1.0" P_Z="0.3172862928834784" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="24.974018837148343" Z="1.0000500659453897">
<NAME>Bevacizumab vs control</NAME>
<DICH_DATA CI_END="1.0961485237682085" CI_START="0.9706677565317102" EFFECT_SIZE="1.0315018315018316" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" LOG_CI_END="0.03986940331150125" LOG_CI_START="-0.01292939645286405" LOG_EFFECT_SIZE="0.013470003429318611" ORDER="220" O_E="0.0" SE="0.031014276339862177" STUDY_ID="STD-ABC-2010" TOTAL_1="65" TOTAL_2="66" VAR="9.618853368853347E-4" WEIGHT="24.974018837148343">
<FOOTNOTE>Control group in the ABC study received standard therapy including pegaptanib injections, verteporfin PDT, or sham injection</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3822178091961588" CI_END="1.294192953501876" CI_START="1.1491362471051132" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2195097513415085" ESTIMABLE="YES" EVENTS_1="741" EVENTS_2="304" I2="27.652502134843786" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.11199903088753073" LOG_CI_START="0.060371523777899484" LOG_EFFECT_SIZE="0.08618527733271511" METHOD="MH" NO="6" P_CHI2="0.23972393060134434" P_Q="1.0" P_Z="5.997500788653086E-11" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.088139650397277E-4" TOTALS="YES" TOTAL_1="757" TOTAL_2="381" WEIGHT="100.0" Z="6.543799963496796">
<NAME>Loss of fewer than 30 letters visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2720162242931592" CI_START="1.100444296211956" EFFECT_SIZE="1.1831242532855437" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="120" LOG_CI_END="0.10449265068036342" LOG_CI_START="0.04156806373621256" LOG_EFFECT_SIZE="0.07303035720828802" ORDER="11" O_E="0.0" SE="0.03696221385272311" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.001366205252894436" WEIGHT="49.0491844865645">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3473955952715997" CI_START="1.1700470142397454" EFFECT_SIZE="1.2555939603420048" ESTIMABLE="YES" EVENTS_1="464" EVENTS_2="184" LOG_CI_END="0.12949512328060095" LOG_CI_START="0.06820331269887397" LOG_EFFECT_SIZE="0.09884921798973749" ORDER="12" O_E="0.0" SE="0.03600311293506199" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.0012962241410148278" WEIGHT="50.9508155134355">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.038834972449767" CI_END="1.8626582938465206" CI_START="1.3406144214669464" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.580223582596989" ESTIMABLE="YES" EVENTS_1="1260" EVENTS_2="354" I2="72.82321904904579" I2_Q="77.48911103273433" ID="CMP-001.07" LOG_CI_END="0.2701331905332764" LOG_CI_START="0.12730388694330202" LOG_EFFECT_SIZE="0.19871853873828924" METHOD="MH" NO="7" P_CHI2="0.011517770961303908" P_Q="0.035059137439565236" P_Z="4.9304844242122555E-8" Q="4.442294577767033" RANDOM="YES" SCALE="2.78" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019480861844340152" TOTALS="YES" TOTAL_1="1768" TOTAL_2="740" WEIGHT="100.0" Z="5.453799314257994">
<NAME>Visual acuity better than 20/200 at 1 year</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.523260253570981" CI_START="1.1529957682329874" DF="0" EFFECT_SIZE="1.3252594562140836" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="131" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.18277411018682962" LOG_CI_START="0.061827713334217764" LOG_EFFECT_SIZE="0.12230091176052371" NO="1" P_CHI2="1.0" P_Z="7.375727531312773E-5" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="28.69752454676331" Z="3.9638284159741994">
<NAME>Pegaptanib vs control</NAME>
<DICH_DATA CI_END="1.523260253570981" CI_START="1.1529957682329874" EFFECT_SIZE="1.3252594562140836" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="131" LOG_CI_END="0.18277411018682962" LOG_CI_START="0.061827713334217764" LOG_EFFECT_SIZE="0.12230091176052371" ORDER="219" O_E="0.0" SE="0.07104451220554422" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" VAR="0.005047322714523721" WEIGHT="28.69752454676331">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.211339453817152" CI_END="2.02793919290917" CI_START="1.4137923553355038" DF="2" EFFECT_SIZE="1.6932468597402552" ESTIMABLE="YES" EVENTS_1="738" EVENTS_2="223" I2="61.622150740246646" ID="CMP-001.07.02" LOG_CI_END="0.30705492867908707" LOG_CI_START="0.15038562901251828" LOG_EFFECT_SIZE="0.22872027884580265" NO="2" P_CHI2="0.07385377551274985" P_Z="1.0486157909417191E-8" STUDIES="3" TAU2="0.0155031290987322" TOTAL_1="878" TOTAL_2="444" WEIGHT="71.3024754532367" Z="5.72267202350161">
<NAME>Ranibizumab vs control</NAME>
<DICH_DATA CI_END="2.494405514491062" CI_START="1.6410126742163413" EFFECT_SIZE="2.023203169213356" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="57" LOG_CI_END="0.39696705795958026" LOG_CI_START="0.21511193530109035" LOG_EFFECT_SIZE="0.3060394966303353" ORDER="62" O_E="0.0" SE="0.10682259924697235" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.011411067709879257" WEIGHT="22.78582751621593">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7289269039754611" CI_START="1.3740668537607539" EFFECT_SIZE="1.5413179916317992" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="136" LOG_CI_END="0.23777663244618238" LOG_CI_START="0.13800786337350535" LOG_EFFECT_SIZE="0.18789224790984388" ORDER="63" O_E="0.0" SE="0.05860466881666232" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.003434507207110673" WEIGHT="30.717296190391114">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.1076405502348687" CI_START="1.2096144266793933" EFFECT_SIZE="1.596694214876033" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="30" LOG_CI_END="0.32379654564844" LOG_CI_START="0.08264695787760891" LOG_EFFECT_SIZE="0.20322175176302446" ORDER="238" O_E="0.0" SE="0.14165246156629757" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.02006541986779141" WEIGHT="17.799351746629643" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7085379461606367" CI_END="1.9765259601629235" CI_START="1.5229680502857499" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7349887284615129" ESTIMABLE="YES" EVENTS_1="715" EVENTS_2="208" I2="26.159424761428653" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2959025228436576" LOG_CI_START="0.18269079254803125" LOG_EFFECT_SIZE="0.2392966576958444" METHOD="MH" NO="8" P_CHI2="0.25813613442073735" P_Q="1.0" P_Z="1.1752777977564233E-16" Q="0.0" RANDOM="YES" SCALE="2.66" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0037969248415158914" TOTALS="YES" TOTAL_1="878" TOTAL_2="444" WEIGHT="100.0" Z="8.285587182175306">
<NAME>Visual acuity better than 20/200 at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4810332482196653" CI_START="1.6193594491342402" EFFECT_SIZE="2.0044162826420893" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="56" LOG_CI_END="0.3946325842728466" LOG_CI_START="0.20934325977791782" LOG_EFFECT_SIZE="0.3019879220253822" ORDER="62" O_E="0.0" SE="0.10883986640526973" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.011846116519116962" WEIGHT="28.2707198263525">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8563853603613685" CI_START="1.4387171949520674" EFFECT_SIZE="1.6342623835875287" ESTIMABLE="YES" EVENTS_1="407" EVENTS_2="124" LOG_CI_END="0.2686681348712413" LOG_CI_START="0.15797543414351478" LOG_EFFECT_SIZE="0.21332178450737804" ORDER="63" O_E="0.0" SE="0.0650214403451722" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" VAR="0.004227787704560786" WEIGHT="55.10976710993951">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.2251112792186913" CI_START="1.2308994387955923" EFFECT_SIZE="1.6549586776859504" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="28" LOG_CI_END="0.3473517352010638" LOG_CI_START="0.09022257367858658" LOG_EFFECT_SIZE="0.2187871544398252" ORDER="64" O_E="0.0" SE="0.1510389422881803" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" VAR="0.02281276208753226" WEIGHT="16.619513063707984">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.037894778378286" CI_END="3.004463998296895" CI_START="1.3066671272138506" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9813718332186017" ESTIMABLE="YES" EVENTS_1="524" EVENTS_2="115" I2="77.87095281542025" I2_Q="77.82862671105443" ID="CMP-001.09" LOG_CI_END="0.47776700434370767" LOG_CI_START="0.11616496537201831" LOG_EFFECT_SIZE="0.29696598485786296" METHOD="MH" NO="9" P_CHI2="0.010900506866544868" P_Q="0.01099495024457875" P_Z="0.0012852897376136778" Q="9.020641048866286" RANDOM="YES" SCALE="9.12" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09523575999456328" TOTALS="YES" TOTAL_1="1183" TOTAL_2="453" WEIGHT="100.0" Z="3.2192442089655806">
<NAME>Maintenance of visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8801386025901357" CI_START="1.1873996819559314" DF="0" EFFECT_SIZE="1.4941472413214825" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="67" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.2741898663494645" LOG_CI_START="0.07459692826462092" LOG_EFFECT_SIZE="0.17439339730704273" NO="1" P_CHI2="1.0" P_Z="6.147569876928122E-4" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="41.39848893777425" Z="3.425018752097259">
<NAME>Pegaptanib vs control</NAME>
<DICH_DATA CI_END="1.8801386025901357" CI_START="1.1873996819559314" EFFECT_SIZE="1.4941472413214825" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="67" LOG_CI_END="0.2741898663494645" LOG_CI_START="0.07459692826462092" LOG_EFFECT_SIZE="0.17439339730704273" ORDER="219" O_E="0.0" SE="0.11724187983201492" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" VAR="0.013745658386544627" WEIGHT="41.39848893777425">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.272397890187944" CI_START="1.9513374297804196" DF="0" EFFECT_SIZE="2.526965074601984" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="43" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.5148661039868011" LOG_CI_START="0.29033237509445725" LOG_EFFECT_SIZE="0.40259923954062915" NO="2" P_CHI2="1.0" P_Z="2.0860108927380954E-12" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="143" WEIGHT="40.05694060488595" Z="7.02861003195813">
<NAME>Ranibizumab vs control</NAME>
<DICH_DATA CI_END="3.272397890187944" CI_START="1.9513374297804196" EFFECT_SIZE="2.526965074601984" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="43" LOG_CI_END="0.5148661039868011" LOG_CI_START="0.29033237509445725" LOG_EFFECT_SIZE="0.40259923954062915" ORDER="62" O_E="0.0" SE="0.13189222381124616" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.017395558701875848" WEIGHT="40.05694060488595">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.676747445325242" CI_START="1.0349072847279668" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.6699439176820475" LOG_CI_START="0.014901443962365112" LOG_EFFECT_SIZE="0.3424226808222063" NO="3" P_CHI2="1.0" P_Z="0.040448649576831926" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="18.544570457339795" Z="2.0491377241237747">
<NAME>Bevacizumab vs control</NAME>
<DICH_DATA CI_END="4.676747445325242" CI_START="1.0349072847279668" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6699439176820475" LOG_CI_START="0.014901443962365112" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="221" O_E="0.0" SE="0.3847751915754809" STUDY_ID="STD-Sacu-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.14805194805194805" WEIGHT="18.544570457339795">
<FOOTNOTE>Control group in the Sacu 2009 study received verteporfin photodynamic therapy plus same day 4 mg intravitreal triamcinolone acetonide</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="217" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="279" TOTAL_2="143" WEIGHT="0.0" Z="0.0">
<NAME>Maintenance of visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.539460947239195" CI_START="2.0791139758043036" EFFECT_SIZE="2.7127371273712737" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="41" LOG_CI_END="0.5489371248886048" LOG_CI_START="0.3178782977519117" LOG_EFFECT_SIZE="0.4334077113202583" ORDER="107" O_E="0.0" SE="0.13572509881973419" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" VAR="0.018421302449626607" WEIGHT="0.0">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="56.11973370688892" CI_END="14.87491940784628" CI_START="11.996869087729548" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="13.435894247787914" ESTIMABLE="YES" I2="94.65428682240568" I2_Q="98.16057834818388" ID="CMP-001.11" NO="11" P_CHI2="3.960720640350246E-12" P_Q="1.6686652060116103E-13" P_Z="8.30572276384251E-75" Q="54.364914048536" RANDOM="YES" SCALE="26.81" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="42.07999454679924" TOTALS="SUB" TOTAL_1="1768" TOTAL_2="740" UNITS="" WEIGHT="200.0" Z="18.299797360516692">
<NAME>Mean change in visual acuity at 1 year (number of letters)</NAME>
<GROUP_LABEL_1>Anti-VEGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors anti-VEGF injection</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.012041212315653" CI_START="4.425558787684347" DF="0" EFFECT_SIZE="6.7188" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="9.336860992945494E-9" STUDIES="1" TAU2="0.0" TOTAL_1="890" TOTAL_2="296" WEIGHT="100.00000000000001" Z="5.742355382681446">
<NAME>Pegaptanib vs control</NAME>
<CONT_DATA CI_END="9.012041212315653" CI_START="4.425558787684347" EFFECT_SIZE="6.7188" ESTIMABLE="YES" MEAN_1="-8.319" MEAN_2="-15.0378" ORDER="245" SD_1="16.3735" SD_2="17.7781" SE="1.1700425264976535" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" WEIGHT="100.00000000000001">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7548196583529134" CI_END="19.647015997391456" CI_START="15.950624685510062" DF="2" EFFECT_SIZE="17.79882034145076" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.4158590497077109" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="878" TOTAL_2="444" WEIGHT="100.0" Z="18.875191446539002">
<NAME>Ranibizumab vs control</NAME>
<CONT_DATA CI_END="22.585078806987354" CI_START="16.204921193012645" EFFECT_SIZE="19.395" ESTIMABLE="YES" MEAN_1="9.895" MEAN_2="-9.5" ORDER="181" SD_1="14.641" SD_2="16.4" SE="1.6276211359750932" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" WEIGHT="33.56549578988067">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="19.6971985446557" CI_START="14.805801455344303" EFFECT_SIZE="17.2515" ESTIMABLE="YES" MEAN_1="6.8515" MEAN_2="-10.4" ORDER="182" SD_1="13.5705" SD_2="16.7" SE="1.247828309064378" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="57.107091260813874">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="21.457359989731938" CI_START="9.354240010268065" EFFECT_SIZE="15.405800000000001" ESTIMABLE="YES" MEAN_1="-0.8942" MEAN_2="-16.3" ORDER="183" SD_1="14.0856" SD_2="22.3" SE="3.087587342148055" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" WEIGHT="9.327412949305462">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6805252493716589" CI_END="22.147720641024275" CI_START="18.077283278302932" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="20.112501959663604" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.711583496702478" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="28.25" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="878" TOTAL_2="444" UNITS="" WEIGHT="100.0" Z="19.36881763171382">
<NAME>Mean change in visual acuity at 2 years (number of letters)</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.66114020626051" CI_START="15.729459793739498" EFFECT_SIZE="19.195300000000003" ESTIMABLE="YES" MEAN_1="9.3953" MEAN_2="-9.8" ORDER="184" SD_1="16.3726" SD_2="17.6" SE="1.768318312784628" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="279" TOTAL_2="143" WEIGHT="34.48300377526773">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="23.67123774906591" CI_START="18.13376225093409" EFFECT_SIZE="20.9025" ESTIMABLE="YES" MEAN_1="6.0025" MEAN_2="-14.9" ORDER="185" SD_1="15.8608" SD_2="18.7" SE="1.4126472582687026" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="54.032929827046885">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="25.15529445061925" CI_START="13.143905549380747" EFFECT_SIZE="19.1496" ESTIMABLE="YES" MEAN_1="-2.2504" MEAN_2="-21.4" ORDER="186" SD_1="14.9444" SD_2="21.8" SE="3.064186126883659" STUDY_ID="STD-PIER-2008" TOTAL_1="121" TOTAL_2="63" WEIGHT="11.48406639768539">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.07" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="890" TOTAL_2="296" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in size of CNV at 1 year (mean number of disc areas)</NAME>
<GROUP_LABEL_1>Pegaptanib</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors pegaptanib</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.41649481965926" CI_START="0.4173051803407402" EFFECT_SIZE="0.9169" ESTIMABLE="YES" ESTIMATE="0.9169" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="183" SE="0.2549" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" WEIGHT="0.0">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.09" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="890" TOTAL_2="296" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in size of lesion at 1 year (mean number of disc areas)</NAME>
<GROUP_LABEL_1>Pegaptanib</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors pegaptanib</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.371182628777322" CI_START="0.3512173712226778" EFFECT_SIZE="0.8612" ESTIMABLE="YES" ESTIMATE="0.8612" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="191" SE="0.2602" STUDY_ID="STD-VISION-2004" TOTAL_1="890" TOTAL_2="296" WEIGHT="0.0">
<FOOTNOTE>Control group in the VISION study received sham injections</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.7347701425402661" CI_END="2.8120704336035165" CI_START="1.8750396065377264" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3435550200706214" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="0.39134138405653063" P_Q="1.0" P_Z="1.083088956836879E-22" Q="0.0" RANDOM="YES" SCALE="4.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="400" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="9.803911039959758">
<NAME>Reduction in size of lesion at 1 year (mean number of disc areas)</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.764948634755985" CI_START="1.7150513652440154" EFFECT_SIZE="2.24" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="-2.56" ORDER="187" SD_1="1.1792" SD_2="3.09" SE="0.26783585764672857" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="280" TOTAL_2="143" WEIGHT="79.65520234368928">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="3.7877168953789493" CI_START="1.71028310462105" EFFECT_SIZE="2.7489999999999997" ESTIMABLE="YES" MEAN_1="1.349" MEAN_2="-1.4" ORDER="188" SD_1="2.5752" SD_2="3.77" SE="0.529967337957338" STUDY_ID="STD-PIER-2008" TOTAL_1="120" TOTAL_2="63" WEIGHT="20.34479765631072">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.47" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="400" TOTAL_2="206" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in size of lesion at 2 years (mean number of disc areas)</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.00288229841431" CI_START="1.86711770158569" EFFECT_SIZE="2.435" ESTIMABLE="YES" MEAN_1="-0.455" MEAN_2="-2.89" ORDER="189" SD_1="1.3392" SD_2="3.33" SE="0.289741190600283" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="280" TOTAL_2="143" WEIGHT="0.0">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.728307914847837" CI_START="-0.5533079148478373" EFFECT_SIZE="0.5874999999999999" ESTIMABLE="YES" MEAN_1="1.3675" MEAN_2="0.78" ORDER="190" SD_1="2.8575" SD_2="4.13" SE="0.5820555499215212" STUDY_ID="STD-PIER-2008" TOTAL_1="120" TOTAL_2="63" WEIGHT="0.0">
<FOOTNOTE>Control group in the PIER study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="152.79512054046737" CI_END="6.0346843582066105" CI_START="4.369645185654815" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="MD" EFFECT_SIZE="5.202164771930713" ESTIMABLE="YES" I2="83.6382209644065" I2_Q="87.35985043124752" ID="CMP-001.17" NO="17" P_CHI2="-1.1102230246251565E-15" P_Q="5.773159728050814E-15" P_Z="1.7384078255612306E-34" Q="94.93558549073676" RANDOM="YES" SCALE="26.81" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="16.45270664305939" TOTALS="SUB" TOTAL_1="9766" TOTAL_2="4914" UNITS="" WEIGHT="1300.0" Z="12.247226086580314">
<NAME>Mean change in quality of life scores at 1 year</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.154663278290709" CI_END="9.992202096040097" CI_START="3.3808763268415127" DF="1" EFFECT_SIZE="6.686539211440805" ESTIMABLE="YES" I2="68.30089579190113" ID="CMP-001.17.01" NO="1" P_CHI2="0.07571063526457555" P_Z="7.354290282671407E-5" STUDIES="2" TAU2="3.93108942107422" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="3.964522848562474">
<NAME>Overall vision-related quality of life</NAME>
<CONT_DATA CI_END="7.871078478599019" CI_START="1.7449215214009812" EFFECT_SIZE="4.808" ESTIMABLE="YES" MEAN_1="7.008" MEAN_2="2.2" ORDER="181" SD_1="15.2556" SD_2="15.0693" SE="1.5628238593975148" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="44.63159598441395">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="10.35363516681744" CI_START="6.0479648331825615" EFFECT_SIZE="8.200800000000001" ESTIMABLE="YES" MEAN_1="5.4008" MEAN_2="-2.8" ORDER="182" SD_1="13.3286" SD_2="14.0958" SE="1.09840547265089" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="55.36840401558605">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.157150344837376" CI_END="16.62102763728238" CI_START="0.2755575058484556" DF="1" EFFECT_SIZE="8.448292571565418" ESTIMABLE="YES" I2="91.03713789728826" ID="CMP-001.17.02" NO="2" P_CHI2="8.370871005404235E-4" P_Z="0.04275992075479982" STUDIES="2" TAU2="31.683495332216236" TOTAL_1="754" TOTAL_2="380" WEIGHT="99.99999999999999" Z="2.026047466115054">
<NAME>Near vision activities</NAME>
<CONT_DATA CI_END="8.128323855356609" CI_START="0.1898761446433901" EFFECT_SIZE="4.1591" ESTIMABLE="YES" MEAN_1="7.8591" MEAN_2="3.7" ORDER="83" SD_1="22.2793" SD_2="18.0831" SE="2.025151424549298" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="48.5893255236076" />
<CONT_DATA CI_END="15.367551287062982" CI_START="9.636648712937019" EFFECT_SIZE="12.5021" ESTIMABLE="YES" MEAN_1="9.9021" MEAN_2="-2.6" ORDER="84" SD_1="19.2392" SD_2="18.0113" SE="1.4619918068216027" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="51.41067447639239" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.56026680096561" CI_END="16.094850989905165" CI_START="3.200462929566279" DF="1" EFFECT_SIZE="9.647656959735722" ESTIMABLE="YES" I2="84.75671751867151" ID="CMP-001.17.03" NO="3" P_CHI2="0.010428105507837682" P_Z="0.003357978079406803" STUDIES="2" TAU2="18.40467457136937" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.932913153814645">
<NAME>Distance vision activities</NAME>
<CONT_DATA CI_END="10.353191676498096" CI_START="1.9678083235019042" EFFECT_SIZE="6.1605" ESTIMABLE="YES" MEAN_1="7.8605" MEAN_2="1.7" ORDER="86" SD_1="21.1335" SD_2="20.4942" SE="2.1391677140853163" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="47.08491586264669" />
<CONT_DATA CI_END="15.552752467223527" CI_START="9.948447532776473" EFFECT_SIZE="12.7506" ESTIMABLE="YES" MEAN_1="6.8506" MEAN_2="-5.9" ORDER="87" SD_1="18.0418" SD_2="18.0113" SE="1.4296958971320635" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="52.915084137353304" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.006411824368433242" CI_END="12.77072296985872" CI_START="6.863155082480745" DF="1" EFFECT_SIZE="9.816939026169733" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.04" NO="4" P_CHI2="0.93617850631084" P_Z="7.319227750287163E-11" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="6.513965576537209">
<NAME>Dependency</NAME>
<CONT_DATA CI_END="14.603902435435028" CI_START="4.705497564564973" EFFECT_SIZE="9.6547" ESTIMABLE="YES" MEAN_1="8.2547" MEAN_2="-1.4" ORDER="86" SD_1="26.1869" SD_2="23.5081" SE="2.5251496836032215" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="35.61943405963051" />
<CONT_DATA CI_END="13.588001013379792" CI_START="6.225398986620211" EFFECT_SIZE="9.9067" ESTIMABLE="YES" MEAN_1="5.2067" MEAN_2="-4.7" ORDER="87" SD_1="22.4207" SD_2="24.2761" SE="1.8782493160167344" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="64.3805659403695" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9467292251882886" CI_END="13.35939088493436" CI_START="6.336374748067068" DF="1" EFFECT_SIZE="9.847882816500714" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.05" NO="5" P_CHI2="0.33055341674311334" P_Z="3.870958411379857E-8" STUDIES="2" TAU2="0.0" TOTAL_1="722" TOTAL_2="358" WEIGHT="100.0" Z="5.4966399815000155">
<NAME>Driving ability</NAME>
<CONT_DATA CI_END="13.377939165685813" CI_START="1.6630608343141864" EFFECT_SIZE="7.5205" ESTIMABLE="YES" MEAN_1="3.4205" MEAN_2="-4.1" ORDER="181" SD_1="30.316" SD_2="24.8952" SE="2.98854428545042" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="244" TOTAL_2="120" WEIGHT="35.93947822793994" />
<CONT_DATA CI_END="15.540911139447356" CI_START="6.766288860552646" EFFECT_SIZE="11.1536" ESTIMABLE="YES" MEAN_1="-1.2464" MEAN_2="-12.4" ORDER="182" SD_1="28.2651" SD_2="28.1916" SE="2.2384651830614772" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="64.06052177206007" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.019529407922811017" CI_END="5.824105906354822" CI_START="0.5407613000488767" DF="1" EFFECT_SIZE="3.182433603201849" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.06" NO="6" P_CHI2="0.8888593780326837" P_Z="0.01821704539022672" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.361176758381777">
<NAME>General health</NAME>
<CONT_DATA CI_END="7.91769423609007" CI_START="-1.0372942360900703" EFFECT_SIZE="3.4402" ESTIMABLE="YES" MEAN_1="-3.5598" MEAN_2="-7.0" ORDER="181" SD_1="20.5098" SD_2="22.9053" SE="2.284477812555727" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="34.8087008603564" />
<CONT_DATA CI_END="6.316580238290216" CI_START="-0.22698023829021574" EFFECT_SIZE="3.0448000000000004" ESTIMABLE="YES" MEAN_1="-3.8552" MEAN_2="-6.9" ORDER="182" SD_1="20.8355" SD_2="21.1437" SE="1.669306305675819" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="65.19129913964359" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.332703462088964" CI_END="13.226776560179736" CI_START="0.75586500727076" DF="1" EFFECT_SIZE="6.991320783725248" ESTIMABLE="YES" I2="69.99433008740621" ID="CMP-001.17.07" NO="7" P_CHI2="0.06791523015092638" P_Z="0.02798106269081932" STUDIES="2" TAU2="14.282922103429174" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.197551779969367">
<NAME>Role difficulties</NAME>
<CONT_DATA CI_END="9.036795884436824" CI_START="-2.013595884436822" EFFECT_SIZE="3.5116000000000005" ESTIMABLE="YES" MEAN_1="7.8116" MEAN_2="4.3" ORDER="181" SD_1="26.4393" SD_2="27.7275" SE="2.8190292923843816" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="45.53063703391697" />
<CONT_DATA CI_END="13.963740473532448" CI_START="5.836259526467549" EFFECT_SIZE="9.899999999999999" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="-3.8" ORDER="182" SD_1="26.7134" SD_2="25.8423" SE="2.0733750750456212" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="54.46936296608303" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.564260975817066" CI_END="11.09806348259832" CI_START="5.7511808114063" DF="1" EFFECT_SIZE="8.42462214700231" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.08" NO="8" P_CHI2="0.45254861931817725" P_Z="6.562430935103111E-10" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="6.176292620164004">
<NAME>Mental health</NAME>
<CONT_DATA CI_END="11.410675140702555" CI_START="2.9017248592974445" EFFECT_SIZE="7.156199999999999" ESTIMABLE="YES" MEAN_1="14.8562" MEAN_2="7.7" ORDER="83" SD_1="24.9365" SD_2="18.6859" SE="2.170690468937854" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="39.48656328408426" />
<CONT_DATA CI_END="12.689024741492798" CI_START="5.815575258507206" EFFECT_SIZE="9.252300000000002" ESTIMABLE="YES" MEAN_1="12.5523" MEAN_2="3.3" ORDER="84" SD_1="22.4514" SD_2="21.9268" SE="1.7534632108555273" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="60.51343671591574" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9278296574557816" CI_END="10.499774486159538" CI_START="5.89679903467017" DF="1" EFFECT_SIZE="8.198286760414854" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.09" NO="9" P_CHI2="0.3354276721944581" P_Z="2.9158432028192856E-12" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.00000000000001" Z="6.981721694885639">
<NAME>General vision</NAME>
<CONT_DATA CI_END="10.580756391764352" CI_START="2.6294436082356487" EFFECT_SIZE="6.6051" ESTIMABLE="YES" MEAN_1="10.5051" MEAN_2="3.9" ORDER="181" SD_1="21.3766" SD_2="18.6859" SE="2.028433391186686" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="33.51194556318946" />
<CONT_DATA CI_END="11.823818847476897" CI_START="6.178781152523105" EFFECT_SIZE="9.0013" ESTIMABLE="YES" MEAN_1="8.5013" MEAN_2="-0.5" ORDER="182" SD_1="18.4326" SD_2="18.0113" SE="1.4400870984061767" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="66.48805443681056" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.329738951497903" CI_END="10.687852165819798" CI_START="5.364974440673823" DF="1" EFFECT_SIZE="8.02641330324681" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.10" NO="10" P_CHI2="0.5658129928051148" P_Z="3.4025750390463342E-9" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="5.910893246741075">
<NAME>Social functioning</NAME>
<CONT_DATA CI_END="11.633282099145838" CI_START="2.1037179008541615" EFFECT_SIZE="6.8685" ESTIMABLE="YES" MEAN_1="6.3685" MEAN_2="-0.5" ORDER="83" SD_1="22.3886" SD_2="24.1109" SE="2.4310559462979073" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="31.19944722241171" />
<CONT_DATA CI_END="11.760136580340609" CI_START="5.342863419659389" EFFECT_SIZE="8.551499999999999" ESTIMABLE="YES" MEAN_1="3.4515" MEAN_2="-5.1" ORDER="84" SD_1="21.1773" SD_2="20.3606" SE="1.6370895616704826" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="68.8005527775883" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.016516241869313154" CI_END="5.047677160548512" CI_START="-0.02428270569823132" DF="1" EFFECT_SIZE="2.51169722742514" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.11" NO="11" P_CHI2="0.8977410120556921" P_Z="0.05223441233380434" STUDIES="2" TAU2="0.0" TOTAL_1="751" TOTAL_2="376" WEIGHT="100.0" Z="1.9411967900547644">
<NAME>Color vision</NAME>
<CONT_DATA CI_END="7.268423875305981" CI_START="-1.7556238753059805" EFFECT_SIZE="2.7564" ESTIMABLE="YES" MEAN_1="1.3564" MEAN_2="-1.4" ORDER="181" SD_1="20.9439" SD_2="22.5747" SE="2.302095299146438" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="273" TOTAL_2="138" WEIGHT="31.589943367386088" />
<CONT_DATA CI_END="5.464796629502002" CI_START="-0.6673966295020026" EFFECT_SIZE="2.3987" ESTIMABLE="YES" MEAN_1="0.4987" MEAN_2="-1.9" ORDER="182" SD_1="20.0" SD_2="19.5775" SE="1.5643637606032463" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="68.41005663261392" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1867374341149244" CI_END="10.025039945499898" CI_START="0.3699152947740618" DF="1" EFFECT_SIZE="5.19747762013698" ESTIMABLE="YES" I2="54.26977265769692" ID="CMP-001.17.12" NO="12" P_CHI2="0.1392039801450644" P_Z="0.03484564629448151" STUDIES="2" TAU2="6.667005275374111" TOTAL_1="753" TOTAL_2="380" WEIGHT="100.0" Z="2.1101475774640823">
<NAME>Peripheral vision</NAME>
<CONT_DATA CI_END="7.622695377417384" CI_START="-2.734695377417384" EFFECT_SIZE="2.444" ESTIMABLE="YES" MEAN_1="5.744" MEAN_2="3.3" ORDER="86" SD_1="26.0514" SD_2="25.3164" SE="2.6422400708718485" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="275" TOTAL_2="142" WEIGHT="44.45049991653929" />
<CONT_DATA CI_END="11.44347128683972" CI_START="3.358128713160279" EFFECT_SIZE="7.4008" ESTIMABLE="YES" MEAN_1="3.7008" MEAN_2="-3.7" ORDER="87" SD_1="24.6948" SD_2="26.6254" SE="2.062625292468533" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="55.549500083460714" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.18246378456402013" CI_END="0.11048019337300685" CI_START="-3.6741791443485528" DF="1" EFFECT_SIZE="-1.781849475487773" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.13" NO="13" P_CHI2="0.6692644033482001" P_Z="0.06495973952828721" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="1.8455350858236514">
<NAME>Ocular pain</NAME>
<CONT_DATA CI_END="0.735009860498768" CI_START="-5.332209860498768" EFFECT_SIZE="-2.2986" ESTIMABLE="YES" MEAN_1="2.5014" MEAN_2="4.8" ORDER="181" SD_1="14.8265" SD_2="15.0693" SE="1.5477885738857935" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="38.911156813780934" />
<CONT_DATA CI_END="0.9684173945764676" CI_START="-3.873817394576468" EFFECT_SIZE="-1.4527" ESTIMABLE="YES" MEAN_1="2.0473" MEAN_2="3.5" ORDER="182" SD_1="16.8752" SD_2="14.8789" SE="1.235286675507271" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="61.08884318621907" />
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="183.21478448444114" CI_END="5.956348454486969" CI_START="3.7370602651050686" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="MD" EFFECT_SIZE="4.846704359796019" ESTIMABLE="YES" I2="86.35481297519249" I2_Q="83.91838291866715" ID="CMP-001.18" NO="18" P_CHI2="-4.440892098500626E-16" P_Q="4.335987124903795E-11" P_Z="1.121528938677309E-17" Q="74.61936159348865" RANDOM="YES" SCALE="26.81" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="24.612415112734247" TOTALS="SUB" TOTAL_1="9766" TOTAL_2="4914" UNITS="" WEIGHT="1300.0" Z="8.560732251325279">
<NAME>Mean change in quality of life scores at 2 years</NAME>
<GROUP_LABEL_1>Ranibizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors ranibizumab</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.85678430009628" CI_END="13.952898290748008" CI_START="3.308042698396653" DF="1" EFFECT_SIZE="8.63047049457233" ESTIMABLE="YES" I2="82.92578403504528" ID="CMP-001.18.01" NO="1" P_CHI2="0.015517156000811605" P_Z="0.0014822405762859262" STUDIES="2" TAU2="12.299702487404248" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="3.178138245698999">
<NAME>Overall vision-related quality of life</NAME>
<CONT_DATA CI_END="9.444999553098908" CI_START="1.9608004469010916" EFFECT_SIZE="5.7029" ESTIMABLE="YES" MEAN_1="5.4029" MEAN_2="-0.3" ORDER="181" SD_1="21.2708" SD_2="16.8776" SE="1.9092695491427962" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="46.24859093780724">
<FOOTNOTE>Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="13.484676372492178" CI_START="8.814123627507822" EFFECT_SIZE="11.1494" ESTIMABLE="YES" MEAN_1="4.6494" MEAN_2="-6.5" ORDER="182" SD_1="15.296" SD_2="14.8789" SE="1.1914894308836999" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="53.751409062192764">
<FOOTNOTE>Control group in the MARINA study received sham injections</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.437373405156364" CI_END="19.554077520741483" CI_START="3.4906577945541137" DF="1" EFFECT_SIZE="11.522367657647798" ESTIMABLE="YES" I2="86.55439298897248" ID="CMP-001.18.02" NO="2" P_CHI2="0.006388344250265687" P_Z="0.0049267721950534095" STUDIES="2" TAU2="29.12159320852894" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.811783046271552">
<NAME>Near vision activities</NAME>
<CONT_DATA CI_END="12.02658740595664" CI_START="2.46841259404336" EFFECT_SIZE="7.2475" ESTIMABLE="YES" MEAN_1="7.4475" MEAN_2="0.2" ORDER="83" SD_1="24.9245" SD_2="22.9053" SE="2.438354706338214" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="47.88716878195076" />
<CONT_DATA CI_END="18.90263550755548" CI_START="11.99856449244452" EFFECT_SIZE="15.450600000000001" ESTIMABLE="YES" MEAN_1="8.7506" MEAN_2="-6.7" ORDER="84" SD_1="22.7418" SD_2="21.9268" SE="1.761274969736534" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="52.112831218049244" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.301714821948668" CI_END="17.903591035063414" CI_START="3.822442571258902" DF="1" EFFECT_SIZE="10.863016803161159" ESTIMABLE="YES" I2="84.13130349032882" ID="CMP-001.18.03" NO="3" P_CHI2="0.012062225251954328" P_Z="0.0024940664344716996" STUDIES="2" TAU2="21.788059800263326" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="3.0240603956954186">
<NAME>Distance vision activities</NAME>
<CONT_DATA CI_END="11.705443180536573" CI_START="2.3995568194634265" EFFECT_SIZE="7.0525" ESTIMABLE="YES" MEAN_1="5.9525" MEAN_2="-1.1" ORDER="86" SD_1="23.1462" SD_2="22.9053" SE="2.3739942250155592" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="47.05335904123777" />
<CONT_DATA CI_END="17.399642880649036" CI_START="11.099157119350968" EFFECT_SIZE="14.249400000000001" ESTIMABLE="YES" MEAN_1="5.8494" MEAN_2="-8.4" ORDER="87" SD_1="21.5659" SD_2="19.5775" SE="1.6072963102882234" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="52.94664095876223" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.88418431125362" CI_END="18.829893905136515" CI_START="3.2947464200134267" DF="1" EFFECT_SIZE="11.06232016257497" ESTIMABLE="YES" I2="79.52575217737164" ID="CMP-001.18.04" NO="4" P_CHI2="0.027103967523852135" P_Z="0.005249427327650489" STUDIES="2" TAU2="25.103953233725612" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.7913155153320943">
<NAME>Dependency</NAME>
<CONT_DATA CI_END="12.583018044093532" CI_START="1.0401819559064682" EFFECT_SIZE="6.8116" ESTIMABLE="YES" MEAN_1="4.6116" MEAN_2="-2.2" ORDER="86" SD_1="28.8652" SD_2="28.3303" SE="2.9446551516342856" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="46.502886308632704" />
<CONT_DATA CI_END="18.800363219423943" CI_START="10.714236780576059" EFFECT_SIZE="14.7573" ESTIMABLE="YES" MEAN_1="4.2573" MEAN_2="-10.5" ORDER="87" SD_1="26.3201" SD_2="25.8423" SE="2.06282526174721" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="53.49711369136729" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9878034541621707" CI_END="17.54895727761047" CI_START="9.509293313014126" DF="1" EFFECT_SIZE="13.529125295312298" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.05" NO="5" P_CHI2="0.32028005521016023" P_Z="4.2113522552292676E-11" STUDIES="2" TAU2="0.0" TOTAL_1="722" TOTAL_2="358" WEIGHT="100.0" Z="6.596444437954387">
<NAME>Driving ability</NAME>
<CONT_DATA CI_END="17.637389360386678" CI_START="3.5626106396133226" EFFECT_SIZE="10.6" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-8.6" ORDER="181" SD_1="35.5411" SD_2="30.4275" SE="3.5905707532876656" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="244" TOTAL_2="120" WEIGHT="32.62816442458545" />
<CONT_DATA CI_END="19.845135343994496" CI_START="10.050264656005506" EFFECT_SIZE="14.947700000000001" ESTIMABLE="YES" MEAN_1="-2.1523" MEAN_2="-17.1" ORDER="182" SD_1="30.2339" SD_2="32.1071" SE="2.4987374169244134" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="67.37183557541455" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04199857646685737" CI_END="5.349137958131914" CI_START="-0.18492898400227897" DF="1" EFFECT_SIZE="2.5821044870648175" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.06" NO="6" P_CHI2="0.8376225993226011" P_Z="0.06740352911605958" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="1.8289738277053156">
<NAME>General health</NAME>
<CONT_DATA CI_END="6.82231130874854" CI_START="-2.433911308748539" EFFECT_SIZE="2.1942000000000004" ESTIMABLE="YES" MEAN_1="-5.0058" MEAN_2="-7.2" ORDER="181" SD_1="22.7857" SD_2="22.9053" SE="2.3613246698686763" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="35.74548831127756" />
<CONT_DATA CI_END="6.249834916433235" CI_START="-0.6540349164332344" EFFECT_SIZE="2.7979000000000003" ESTIMABLE="YES" MEAN_1="-6.2021" MEAN_2="-9.0" ORDER="182" SD_1="22.7399" SD_2="21.9268" SE="1.761223646792317" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="64.25451168872245" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.6248735950466395" CI_END="17.540356036315437" CI_START="1.3367093971208686" DF="1" EFFECT_SIZE="9.438532716718152" ESTIMABLE="YES" I2="78.37778742599525" ID="CMP-001.18.07" NO="7" P_CHI2="0.031511649087545" P_Z="0.022410588791549044" STUDIES="2" TAU2="26.90752959249552" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.2833359185855597">
<NAME>Role difficulties</NAME>
<CONT_DATA CI_END="11.132523254409623" CI_START="-1.1007232544096226" EFFECT_SIZE="5.0159" ESTIMABLE="YES" MEAN_1="5.7159" MEAN_2="0.7" ORDER="181" SD_1="31.5034" SD_2="29.5358" SE="3.1207834953380607" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="46.62652703629947" />
<CONT_DATA CI_END="17.731255055949916" CI_START="8.872944944050083" EFFECT_SIZE="13.3021" ESTIMABLE="YES" MEAN_1="6.2021" MEAN_2="-7.1" ORDER="182" SD_1="29.0658" SD_2="28.1916" SE="2.2598145123515163" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="53.37347296370053" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.845109799838322" CI_END="16.170079834511867" CI_START="3.975435276033086" DF="1" EFFECT_SIZE="10.072757555272476" ESTIMABLE="YES" I2="73.99294033054537" ID="CMP-001.18.08" NO="8" P_CHI2="0.049891304458833274" P_Z="0.0012043223711413094" STUDIES="2" TAU2="14.408307995946478" TOTAL_1="754" TOTAL_2="380" WEIGHT="99.99999999999999" Z="3.237854443180347">
<NAME>Mental health</NAME>
<CONT_DATA CI_END="11.735331902626388" CI_START="1.6864680973736137" EFFECT_SIZE="6.7109000000000005" ESTIMABLE="YES" MEAN_1="12.1109" MEAN_2="5.4" ORDER="83" SD_1="26.1509" SD_2="24.1109" SE="2.5635327701215247" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="46.12925751894885" />
<CONT_DATA CI_END="16.647875735026357" CI_START="9.25512426497364" EFFECT_SIZE="12.9515" ESTIMABLE="YES" MEAN_1="12.2515" MEAN_2="-0.7" ORDER="84" SD_1="24.324" SD_2="23.493" SE="1.8859406418602072" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="53.87074248105114" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5565685958691775" CI_END="13.72140264931658" CI_START="5.490478539490897" DF="1" EFFECT_SIZE="9.605940594403739" ESTIMABLE="YES" I2="60.885070652288846" ID="CMP-001.18.09" NO="9" P_CHI2="0.10983709771250583" P_Z="4.7674051997645635E-6" STUDIES="2" TAU2="5.500494423305165" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="4.574771277550106">
<NAME>General vision</NAME>
<CONT_DATA CI_END="11.504209282020826" CI_START="2.7993907179791755" EFFECT_SIZE="7.151800000000001" ESTIMABLE="YES" MEAN_1="10.9518" MEAN_2="3.8" ORDER="181" SD_1="22.27" SD_2="21.097" SE="2.220657785730796" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="42.26502471584121" />
<CONT_DATA CI_END="14.267093568326162" CI_START="8.537906431673838" EFFECT_SIZE="11.4025" ESTIMABLE="YES" MEAN_1="9.1025" MEAN_2="-2.3" ORDER="182" SD_1="19.2233" SD_2="18.0113" SE="1.4615541871798208" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="57.73497528415879" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.311742921061405" CI_END="14.469627248672552" CI_START="1.769701909134045" DF="1" EFFECT_SIZE="8.119664578903299" ESTIMABLE="YES" I2="76.80752265828886" ID="CMP-001.18.10" NO="10" P_CHI2="0.037850351054478315" P_Z="0.012203799871958992" STUDIES="2" TAU2="16.197144451800682" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="2.5061958579631063">
<NAME>Social functioning</NAME>
<CONT_DATA CI_END="9.57626869924233" CI_START="-0.26686869924233036" EFFECT_SIZE="4.6547" ESTIMABLE="YES" MEAN_1="4.2547" MEAN_2="-0.4" ORDER="83" SD_1="25.81" SD_2="23.5081" SE="2.5110505795326015" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="46.64606533570517" />
<CONT_DATA CI_END="14.80330466361185" CI_START="7.49469533638815" EFFECT_SIZE="11.149000000000001" ESTIMABLE="YES" MEAN_1="1.649" MEAN_2="-9.5" ORDER="84" SD_1="23.5197" SD_2="23.493" SE="1.8644754150772869" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="53.353934664294826" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8694136711066136" CI_END="8.507723986036577" CI_START="2.886053793231272" DF="1" EFFECT_SIZE="5.696888889633924" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.11" NO="11" P_CHI2="0.3511177744038083" P_Z="7.115894342603647E-5" STUDIES="2" TAU2="0.0" TOTAL_1="751" TOTAL_2="376" WEIGHT="100.0" Z="3.9723771280282127">
<NAME>Color vision</NAME>
<CONT_DATA CI_END="8.675787419145808" CI_START="-1.0683874191458078" EFFECT_SIZE="3.8036999999999996" ESTIMABLE="YES" MEAN_1="-0.4963" MEAN_2="-4.3" ORDER="181" SD_1="21.3391" SD_2="24.951" SE="2.4858045645614975" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="273" TOTAL_2="138" WEIGHT="33.28438913084808" />
<CONT_DATA CI_END="10.082692865405559" CI_START="3.2001071345944423" EFFECT_SIZE="6.6414" ESTIMABLE="YES" MEAN_1="-0.4586" MEAN_2="-7.1" ORDER="182" SD_1="22.5383" SD_2="21.9268" SE="1.7557939291487172" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="66.71561086915192" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4944143400269416" CI_END="12.093695990640105" CI_START="1.4772829766459967" DF="1" EFFECT_SIZE="6.785489483643051" ESTIMABLE="YES" I2="59.91042931587704" ID="CMP-001.18.12" NO="12" P_CHI2="0.11425114525216906" P_Z="0.01223042218497578" STUDIES="2" TAU2="8.955006506846898" TOTAL_1="753" TOTAL_2="380" WEIGHT="100.0" Z="2.5054253235787027">
<NAME>Peripheral vision</NAME>
<CONT_DATA CI_END="9.232744807179145" CI_START="-1.8741448071791456" EFFECT_SIZE="3.6793" ESTIMABLE="YES" MEAN_1="2.2793" MEAN_2="-1.4" ORDER="86" SD_1="27.9811" SD_2="27.1247" SE="2.8334422729111397" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="275" TOTAL_2="142" WEIGHT="43.18916007676033" />
<CONT_DATA CI_END="13.045327800476475" CI_START="5.2484721995235235" EFFECT_SIZE="9.146899999999999" ESTIMABLE="YES" MEAN_1="2.0469" MEAN_2="-7.1" ORDER="87" SD_1="25.0974" SD_2="25.0592" SE="1.9890303246522774" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="56.81083992323967" />
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04192711310257839" CI_END="0.9212956609050287" CI_START="-3.1270463768037673" DF="1" EFFECT_SIZE="-1.1028753579493693" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.13" NO="13" P_CHI2="0.8377588839425032" P_Z="0.2855692602298803" STUDIES="2" TAU2="0.0" TOTAL_1="754" TOTAL_2="380" WEIGHT="100.0" Z="1.06789197201374">
<NAME>Ocular pain</NAME>
<CONT_DATA CI_END="2.704032821844442" CI_START="-4.311232821844443" EFFECT_SIZE="-0.8036000000000001" ESTIMABLE="YES" MEAN_1="1.6964" MEAN_2="2.5" ORDER="181" SD_1="15.7608" SD_2="18.0831" SE="1.7896414676556316" STUDY_ID="STD-ANCHOR-2006" TOTAL_1="276" TOTAL_2="142" WEIGHT="33.30168086708956" />
<CONT_DATA CI_END="1.2262047630711266" CI_START="-3.730804763071127" EFFECT_SIZE="-1.2523000000000002" ESTIMABLE="YES" MEAN_1="1.9477" MEAN_2="3.2" ORDER="182" SD_1="16.4841" SD_2="15.662" SE="1.26456648317074" STUDY_ID="STD-MARINA-2006" TOTAL_1="478" TOTAL_2="238" WEIGHT="66.69831913291044" />
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Bevacizumab versus ranibizumab</NAME>
<DICH_OUTCOME CHI2="9.310088137726538" CI_END="1.1159864068602137" CI_START="0.8131669233329686" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9526191437022113" ESTIMABLE="YES" EVENTS_1="371" EVENTS_2="403" I2="24.812741872609664" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.04765890476145799" LOG_CI_START="-0.08982029519155649" LOG_EFFECT_SIZE="-0.021080695215049267" METHOD="MH" NO="1" P_CHI2="0.23115304496039235" P_Q="1.0" P_Z="0.5477924753141816" Q="0.0" RANDOM="YES" SCALE="18.31" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01228950750666457" TOTALS="YES" TOTAL_1="1542" TOTAL_2="1602" WEIGHT="100.00000000000001" Z="0.6010713388597428">
<NAME>Gain of 15 or more letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1109968695482286" CI_START="0.19283288780191962" EFFECT_SIZE="0.46285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.04571283523263579" LOG_CI_START="-0.7148188948479253" LOG_EFFECT_SIZE="-0.3345530298076447" ORDER="137" O_E="0.0" SE="0.44674010294210165" STUDY_ID="STD-Biswas-2011" TOTAL_1="50" TOTAL_2="54" VAR="0.19957671957671957" WEIGHT="3.0781335859303485">
<FOOTNOTE>follow-up was 18 months</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.901393297978792" CI_START="0.830465743560336" EFFECT_SIZE="1.2565993788819876" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.27907195877771085" LOG_CI_START="-0.08067827734811363" LOG_EFFECT_SIZE="0.09919684071479862" ORDER="155" O_E="0.0" SE="0.21131906949269835" STUDY_ID="STD-BRAMD-2016" TOTAL_1="161" TOTAL_2="166" VAR="0.04465574913125987" WEIGHT="11.452271669549202" />
<DICH_DATA CI_END="1.2051957235061483" CI_START="0.8375544619911187" EFFECT_SIZE="1.0046974946695095" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="168" LOG_CI_END="0.08105758196167732" LOG_CI_START="-0.07698694336789781" LOG_EFFECT_SIZE="0.0020353192968897526" ORDER="133" O_E="0.0" SE="0.09283613651161013" STUDY_ID="STD-CATT-2011" TOTAL_1="536" TOTAL_2="569" VAR="0.008618548242402312" WEIGHT="31.1914487476348" />
<DICH_DATA CI_END="1.4219750943567608" CI_START="0.6455701706800375" EFFECT_SIZE="0.9581151832460733" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" LOG_CI_END="0.1528919898690288" LOG_CI_START="-0.19005654490362495" LOG_EFFECT_SIZE="-0.018582277517298088" ORDER="239" O_E="0.0" SE="0.20144966694808286" STUDY_ID="STD-GEFAL-2013" TOTAL_1="191" TOTAL_2="183" VAR="0.040581968313493505" WEIGHT="12.334676480906316" />
<DICH_DATA CI_END="0.9703885707020503" CI_START="0.47620309430547475" EFFECT_SIZE="0.6797808764940239" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="64" LOG_CI_END="-0.013054327259231521" LOG_CI_START="-0.3222077869331823" LOG_EFFECT_SIZE="-0.1676310570962069" ORDER="134" O_E="0.0" SE="0.181598272546785" STUDY_ID="STD-IVAN-2013" TOTAL_1="251" TOTAL_2="273" VAR="0.032977932591976414" WEIGHT="14.40665846994272" />
<DICH_DATA CI_END="1.3452205969963371" CI_START="0.6784373763362358" EFFECT_SIZE="0.9553260869565218" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" LOG_CI_END="0.12879350828084649" LOG_CI_START="-0.16849023402752414" LOG_EFFECT_SIZE="-0.019848362873338823" ORDER="151" O_E="0.0" SE="0.17462594181019467" STUDY_ID="STD-LUCAS-2015" TOTAL_1="184" TOTAL_2="187" VAR="0.030494219553097494" WEIGHT="15.243004621798315" />
<DICH_DATA CI_END="1.640149175928097" CI_START="0.7226355617242551" EFFECT_SIZE="1.088682745825603" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.21488335008188916" LOG_CI_START="-0.14108067011287637" LOG_EFFECT_SIZE="0.03690133998450638" ORDER="138" O_E="0.0" SE="0.2090950275127232" STUDY_ID="STD-MANTA-2013" TOTAL_1="154" TOTAL_2="163" VAR="0.043720730530546474" WEIGHT="11.643452557306501" />
<DICH_DATA CI_END="16.4102535319945" CI_START="0.3317708915239854" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2151152907846978" LOG_CI_START="-0.47916172019550907" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="135" O_E="0.0" SE="0.9952267030562386" STUDY_ID="STD-Subramanian-2010" TOTAL_1="15" TOTAL_2="7" VAR="0.9904761904761905" WEIGHT="0.6503538669317956" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9561508820722997" CI_END="1.0221850720637076" CI_START="0.6921450298236314" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8411303806121888" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="413" I2="24.168716274326005" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.009529534252071445" LOG_CI_START="-0.15980289535140843" LOG_EFFECT_SIZE="-0.0751366805496685" METHOD="MH" NO="2" P_CHI2="0.2662382066721375" P_Q="0.9878558796529978" P_Z="0.08197112645023769" Q="2.3167839895558756E-4" RANDOM="YES" SCALE="25.06" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0055294593305685626" TOTALS="SUB" TOTAL_1="1380" TOTAL_2="1462" WEIGHT="200.0" Z="1.7393618947072025">
<NAME>Gain of 15 or more letters visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.006687535826724" CI_END="1.1062055627510932" CI_START="0.641467663883668" DF="1" EFFECT_SIZE="0.8423746779866202" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="225" I2="50.166631219542836" ID="CMP-002.02.01" LOG_CI_END="0.04383583806555468" LOG_CI_START="-0.19282523134025156" LOG_EFFECT_SIZE="-0.07449469663734842" NO="1" P_CHI2="0.15660730128927836" P_Z="0.2172437340231368" STUDIES="2" TAU2="0.02101317529003634" TOTAL_1="751" TOTAL_2="796" WEIGHT="100.0" Z="1.2338904984670702">
<NAME>Participants in groups as randomized at baseline</NAME>
<DICH_DATA CI_END="1.1286541668277787" CI_START="0.7744519482051383" EFFECT_SIZE="0.9349269588313412" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="162" LOG_CI_END="0.0525608892708135" LOG_CI_START="-0.11100552338799029" LOG_EFFECT_SIZE="-0.02922231705858839" ORDER="133" O_E="0.0" SE="0.09607972046258216" STUDY_ID="STD-CATT-2011" TOTAL_1="502" TOTAL_2="528" VAR="0.009231312684167929" WEIGHT="63.89731552505457" />
<DICH_DATA CI_END="0.9973985079771022" CI_START="0.49191355974596257" EFFECT_SIZE="0.7004526040670619" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="63" LOG_CI_END="-0.0011312857845858684" LOG_CI_START="-0.3081112058170016" LOG_EFFECT_SIZE="-0.15462124580079373" ORDER="134" O_E="0.0" SE="0.18032152460215253" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="0.0325158522348447" WEIGHT="36.10268447494543" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9430972660090302" CI_END="1.1101531409173484" CI_START="0.6353264092566493" DF="1" EFFECT_SIZE="0.8398271302738498" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="188" I2="48.53577237263465" ID="CMP-002.02.02" LOG_CI_END="0.04538289200096481" LOG_CI_START="-0.19700309153070594" LOG_EFFECT_SIZE="-0.07581009976487058" NO="2" P_CHI2="0.16333291160098806" P_Z="0.22019106808213962" STUDIES="2" TAU2="0.02088973737259208" TOTAL_1="629" TOTAL_2="666" WEIGHT="100.00000000000001" Z="1.2260202759135228">
<NAME>Participants remaining in same groups after re-randomization</NAME>
<DICH_DATA CI_END="1.1609422481878071" CI_START="0.7585851805337005" EFFECT_SIZE="0.9384421052631579" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="125" LOG_CI_END="0.06481061602006617" LOG_CI_START="-0.11999564578206047" LOG_EFFECT_SIZE="-0.02759251488099713" ORDER="133" O_E="0.0" SE="0.10855611298831888" STUDY_ID="STD-CATT-2011" TOTAL_1="380" TOTAL_2="398" VAR="0.011784429667132655" WEIGHT="62.04198488425657" />
<DICH_DATA CI_END="0.9973985079771022" CI_START="0.49191355974596257" EFFECT_SIZE="0.7004526040670619" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="63" LOG_CI_END="-0.0011312857845858684" LOG_CI_START="-0.3081112058170016" LOG_EFFECT_SIZE="-0.15462124580079373" ORDER="134" O_E="0.0" SE="0.18032152460215253" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="0.0325158522348447" WEIGHT="37.95801511574344" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.977980659779252" CI_END="1.0162066312530087" CI_START="0.9754596232439221" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9956246971926898" ESTIMABLE="YES" EVENTS_1="1442" EVENTS_2="1513" I2="22.03146492217868" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.006982024570727682" LOG_CI_START="-0.010790702451189666" LOG_EFFECT_SIZE="-0.001904338940230986" METHOD="MH" NO="3" P_CHI2="0.25424095412317693" P_Q="1.0" P_Z="0.6744720499066695" Q="0.0" RANDOM="YES" SCALE="2.03" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.8579605748939785E-4" TOTALS="YES" TOTAL_1="1542" TOTAL_2="1602" WEIGHT="99.99999999999999" Z="0.42001834975657193">
<NAME>Loss of fewer than 15 letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1056989344948762" CI_START="0.9732228233047444" EFFECT_SIZE="1.0373482726423904" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="52" LOG_CI_END="0.04363689108554455" LOG_CI_START="-0.011787714867520508" LOG_EFFECT_SIZE="0.015924588109012018" ORDER="279" O_E="0.0" SE="0.032556687893054666" STUDY_ID="STD-Biswas-2011" TOTAL_1="50" TOTAL_2="54" VAR="0.0010599379265657724" WEIGHT="8.748992265721816">
<FOOTNOTE>follow-up was 18 months</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9954581326081917" CI_START="0.8747809684068968" EFFECT_SIZE="0.9331708467646828" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="158" LOG_CI_END="-0.0019770009902613074" LOG_CI_START="-0.058100673972049544" LOG_EFFECT_SIZE="-0.030038837481155423" ORDER="156" O_E="0.0" SE="0.03296732332616427" STUDY_ID="STD-BRAMD-2016" TOTAL_1="161" TOTAL_2="166" VAR="0.0010868444072918548" WEIGHT="8.564018898706685" />
<DICH_DATA CI_END="1.0072061469180762" CI_START="0.9477675686684128" EFFECT_SIZE="0.9770349640685462" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="540" LOG_CI_END="0.003118367580798108" LOG_CI_START="-0.023298156355468582" LOG_EFFECT_SIZE="-0.01008989438733523" ORDER="127" O_E="0.0" SE="0.01551719692406551" STUDY_ID="STD-CATT-2011" TOTAL_1="536" TOTAL_2="569" VAR="2.4078340038022816E-4" WEIGHT="25.549558917055272" />
<DICH_DATA CI_END="1.0784802075968778" CI_START="0.9465724797435516" EFFECT_SIZE="1.010376011423132" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="165" LOG_CI_END="0.03281217928526384" LOG_CI_START="-0.023846126182472963" LOG_EFFECT_SIZE="0.004483026551395411" ORDER="240" O_E="0.0" SE="0.03328136909488389" STUDY_ID="STD-GEFAL-2013" TOTAL_1="191" TOTAL_2="183" VAR="0.0011076495288298927" WEIGHT="8.42626632841985" />
<DICH_DATA CI_END="1.0423312780880862" CI_START="0.9670476377748886" EFFECT_SIZE="1.00398406374502" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="260" LOG_CI_END="0.018005770192074996" LOG_CI_START="-0.014552131591063071" LOG_EFFECT_SIZE="0.0017268193005059549" ORDER="128" O_E="0.0" SE="0.019124672671628366" STUDY_ID="STD-IVAN-2013" TOTAL_1="251" TOTAL_2="273" VAR="3.6575310479692886E-4" WEIGHT="19.760553975762424" />
<DICH_DATA CI_END="1.0478026116399997" CI_START="0.9638480237321239" EFFECT_SIZE="1.0049489919844548" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="179" LOG_CI_END="0.02027947658895266" LOG_CI_START="-0.015991438771200666" LOG_EFFECT_SIZE="0.002144018908875986" ORDER="152" O_E="0.0" SE="0.02130571522648072" STUDY_ID="STD-LUCAS-2015" TOTAL_1="184" TOTAL_2="187" VAR="4.539335013118923E-4" WEIGHT="17.036756925954204" />
<DICH_DATA CI_END="1.0659692081555459" CI_START="0.9570000430921274" EFFECT_SIZE="1.0100161276631865" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="153" LOG_CI_END="0.027744659736260655" LOG_CI_START="-0.01908804266759456" LOG_EFFECT_SIZE="0.0043283085343330365" ORDER="280" O_E="0.0" SE="0.027509761217640254" STUDY_ID="STD-MANTA-2013" TOTAL_1="154" TOTAL_2="163" VAR="7.567869622515837E-4" WEIGHT="11.562819150551313" />
<DICH_DATA CI_END="1.682381854009893" CI_START="0.8449910641557212" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.2259245754498575" LOG_CI_START="-0.07314788372294807" LOG_EFFECT_SIZE="0.0763883458634547" ORDER="129" O_E="0.0" SE="0.175676642950655" STUDY_ID="STD-Subramanian-2010" TOTAL_1="15" TOTAL_2="7" VAR="0.030862282878411917" WEIGHT="0.3510335378284207" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.426052557559005" CI_END="0.997489217617164" CI_START="0.9523617910695527" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9746643616458176" ESTIMABLE="YES" EVENTS_1="1240" EVENTS_2="1348" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.0010917901321177966" LOG_CI_START="-0.021198036892235414" LOG_EFFECT_SIZE="-0.011144913512176603" METHOD="MH" NO="4" P_CHI2="0.6994394092681131" P_Q="0.9126787675456685" P_Z="0.029793855796969828" Q="0.012025387030693079" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1380" TOTAL_2="1462" WEIGHT="200.0" Z="2.1728201543819257">
<NAME>Loss of fewer than 15 letters visual acuity at 2 years</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7803742907090547" CI_END="1.0048661805454953" CI_START="0.9430772020547822" DF="1" EFFECT_SIZE="0.9734815796861906" ESTIMABLE="YES" EVENTS_1="673" EVENTS_2="733" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.0021082299950589433" LOG_CI_START="-0.025452753652919394" LOG_EFFECT_SIZE="-0.011672261828930252" NO="1" P_CHI2="0.37702673630460093" P_Z="0.09689115029647644" STUDIES="2" TAU2="0.0" TOTAL_1="751" TOTAL_2="796" WEIGHT="99.99999999999999" Z="1.6601158431080172">
<NAME>Participants in groups as randomized at baseline</NAME>
<DICH_DATA CI_END="1.0019574726635936" CI_START="0.9263743561233344" EFFECT_SIZE="0.9634249885703089" ESTIMABLE="YES" EVENTS_1="447" EVENTS_2="488" LOG_CI_END="8.492886175687467E-4" LOG_CI_START="-0.03321347558153116" LOG_EFFECT_SIZE="-0.016182093481981234" ORDER="127" O_E="0.0" SE="0.020008636303953418" STUDY_ID="STD-CATT-2011" TOTAL_1="502" TOTAL_2="528" VAR="4.0034552674388275E-4" WEIGHT="65.46808695849701" />
<DICH_DATA CI_END="1.0479207149937386" CI_START="0.9406480899814229" EFFECT_SIZE="0.9928366527333825" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="245" LOG_CI_END="0.020328425449926385" LOG_CI_START="-0.02657282201808447" LOG_EFFECT_SIZE="-0.0031221982840790655" ORDER="128" O_E="0.0" SE="0.027550024927628834" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="7.590038735129701E-4" WEIGHT="34.531913041502975" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6339896503180902" CI_END="1.009609458082822" CI_START="0.943532015951032" DF="1" EFFECT_SIZE="0.9760117044934011" ESTIMABLE="YES" EVENTS_1="567" EVENTS_2="615" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.004153410416242602" LOG_CI_START="-0.025243358758231582" LOG_EFFECT_SIZE="-0.01054497417099446" NO="2" P_CHI2="0.4258958815093443" P_Z="0.15968693793287483" STUDIES="2" TAU2="0.0" TOTAL_1="629" TOTAL_2="666" WEIGHT="100.0" Z="1.4061252425658053">
<NAME>Participants remaining in same groups after re-randomization</NAME>
<DICH_DATA CI_END="1.008127943372903" CI_START="0.9242481885088254" EFFECT_SIZE="0.9652773826458036" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="370" LOG_CI_END="0.003515652719391444" LOG_CI_START="-0.034211391954630674" LOG_EFFECT_SIZE="-0.01534786961761961" ORDER="133" O_E="0.0" SE="0.022161052793403656" STUDY_ID="STD-CATT-2011" TOTAL_1="380" TOTAL_2="398" VAR="4.911122609120239E-4" WEIGHT="60.71466903049636" />
<DICH_DATA CI_END="1.0479207149937386" CI_START="0.9406480899814229" EFFECT_SIZE="0.9928366527333825" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="245" LOG_CI_END="0.020328425449926385" LOG_CI_START="-0.02657282201808447" LOG_EFFECT_SIZE="-0.0031221982840790655" ORDER="134" O_E="0.0" SE="0.027550024927628834" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="7.590038735129701E-4" WEIGHT="39.28533096950363" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0482636302713964" CI_END="1.0085192548329445" CI_START="0.958148692541413" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9830113963841038" ESTIMABLE="YES" EVENTS_1="899" EVENTS_2="947" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.0036841942571335475" LOG_CI_START="-0.018567088688406744" LOG_EFFECT_SIZE="-0.007441447215636626" METHOD="MH" NO="5" P_CHI2="0.5624501171663512" P_Q="1.0" P_Z="0.18988046185533758" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="1032" WEIGHT="99.99999999999997" Z="1.3109328186783782">
<NAME>Visual acuity better than 20/200 at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0162272610520124" CI_START="0.9528663629140731" EFFECT_SIZE="0.9840369780311924" ESTIMABLE="YES" EVENTS_1="495" EVENTS_2="534" LOG_CI_END="0.006990841002990821" LOG_CI_START="-0.02096800378836388" LOG_EFFECT_SIZE="-0.006988581392686529" ORDER="130" O_E="0.0" SE="0.016423163828955527" STUDY_ID="STD-CATT-2011" TOTAL_1="536" TOTAL_2="569" VAR="2.697203101527132E-4" WEIGHT="63.33906761996455" />
<DICH_DATA CI_END="1.1354968207970668" CI_START="0.9439059801783057" EFFECT_SIZE="1.03527882216522" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="149" LOG_CI_END="0.05518592260487455" LOG_CI_START="-0.025071262400319417" LOG_EFFECT_SIZE="0.015057330102277566" ORDER="241" O_E="0.0" SE="0.047143467751523935" STUDY_ID="STD-GEFAL-2013" TOTAL_1="191" TOTAL_2="183" VAR="0.0022225065516389775" WEIGHT="7.68674132845283" />
<DICH_DATA CI_END="1.0175104477484718" CI_START="0.923793199054971" EFFECT_SIZE="0.9695201037613489" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="257" LOG_CI_END="0.007538877235060716" LOG_CI_START="-0.03442523934404017" LOG_EFFECT_SIZE="-0.013443181054489719" ORDER="131" O_E="0.0" SE="0.024649929804291076" STUDY_ID="STD-IVAN-2013" TOTAL_1="252" TOTAL_2="273" VAR="6.076190393564775E-4" WEIGHT="28.116026419010517" />
<DICH_DATA CI_END="1.186701824006791" CI_START="0.682564047356992" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.07434160989307546" LOG_CI_START="-0.16585659101442563" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="132" O_E="0.0" SE="0.14109361221333658" STUDY_ID="STD-Subramanian-2010" TOTAL_1="15" TOTAL_2="7" VAR="0.0199074074074074" WEIGHT="0.8581646325720819" />
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.78716288412336" CI_END="1.0437577364213888" CI_START="0.9657688488773745" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0040063284713592" ESTIMABLE="YES" EVENTS_1="1236" EVENTS_2="1303" I2="20.785028481962694" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.01859970753133939" LOG_CI_START="-0.0151268069899754" LOG_EFFECT_SIZE="0.0017364502706820125" METHOD="MH" NO="6" P_CHI2="0.28538313658719605" P_Q="0.9473940633455791" P_Z="0.8400557112259386" Q="0.0043533082120942755" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.6936235995960563E-4" TOTALS="SUB" TOTAL_1="1380" TOTAL_2="1462" WEIGHT="200.0" Z="0.20182221849996518">
<NAME>Visual acuity better than 20/200 at 2 years</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0181138777164405" CI_END="1.0615036051573348" CI_START="0.9469507549302492" DF="1" EFFECT_SIZE="1.0025924597087887" ESTIMABLE="YES" EVENTS_1="672" EVENTS_2="711" I2="50.44878234861892" ID="CMP-002.06.01" LOG_CI_END="0.025921473487677624" LOG_CI_START="-0.023672605387585612" LOG_EFFECT_SIZE="0.0011244340500459816" NO="1" P_CHI2="0.15543249143313864" P_Z="0.9291808238073501" STUDIES="2" TAU2="9.624783383078964E-4" TOTAL_1="751" TOTAL_2="796" WEIGHT="100.00000000000001" Z="0.08887553881678795">
<NAME>Participants in groups as randomized at baseline</NAME>
<DICH_DATA CI_END="1.0181467017702555" CI_START="0.9500753805024227" EFFECT_SIZE="0.9835223002513274" ESTIMABLE="YES" EVENTS_1="461" EVENTS_2="493" LOG_CI_END="0.0078103587267379605" LOG_CI_START="-0.022241935724315844" LOG_EFFECT_SIZE="-0.00721578849878894" ORDER="127" O_E="0.0" SE="0.017652866521805744" STUDY_ID="STD-CATT-2011" TOTAL_1="502" TOTAL_2="528" VAR="3.1162369643669E-4" WEIGHT="66.60865305614806" />
<DICH_DATA CI_END="1.1261239666577465" CI_START="0.9636883655234142" EFFECT_SIZE="1.0417449614973655" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="218" LOG_CI_END="0.05158620141406189" LOG_CI_START="-0.016063384161781352" LOG_EFFECT_SIZE="0.017761408626140274" ORDER="128" O_E="0.0" SE="0.03973770143809965" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="0.0015790849155835466" WEIGHT="33.39134694385196" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7310353050576697" CI_END="1.059896963487048" CI_START="0.9533719310138905" DF="1" EFFECT_SIZE="1.0052243604068725" ESTIMABLE="YES" EVENTS_1="564" EVENTS_2="592" I2="42.23110313936174" ID="CMP-002.06.02" LOG_CI_END="0.025263647940234623" LOG_CI_START="-0.020737638632208424" LOG_EFFECT_SIZE="0.0022630046540130524" NO="2" P_CHI2="0.18827883608175933" P_Z="0.8470855165811257" STUDIES="2" TAU2="7.096894891551914E-4" TOTAL_1="629" TOTAL_2="666" WEIGHT="100.0" Z="0.19283841601809426">
<NAME>Participants remaining in same groups after re-randomization</NAME>
<DICH_DATA CI_END="1.0261464233991813" CI_START="0.9523483233248705" EFFECT_SIZE="0.9885589642555587" ESTIMABLE="YES" EVENTS_1="353" EVENTS_2="374" LOG_CI_END="0.011209335763224073" LOG_CI_START="-0.02120417847478389" LOG_EFFECT_SIZE="-0.004997421355779916" ORDER="133" O_E="0.0" SE="0.019039858712889053" STUDY_ID="STD-CATT-2011" TOTAL_1="380" TOTAL_2="398" VAR="3.625162198067772E-4" WEIGHT="68.09842151129585" />
<DICH_DATA CI_END="1.1261239666577465" CI_START="0.9636883655234142" EFFECT_SIZE="1.0417449614973655" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="218" LOG_CI_END="0.05158620141406189" LOG_CI_START="-0.016063384161781352" LOG_EFFECT_SIZE="0.017761408626140274" ORDER="134" O_E="0.0" SE="0.03973770143809965" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" VAR="0.0015790849155835466" WEIGHT="31.90157848870414" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.784557990675577" CI_END="0.45493717929703825" CI_START="-1.4876591062372977" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5163609634701297" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.5600458831615609" P_Q="1.0" P_Z="0.29743258865480293" Q="0.0" RANDOM="YES" SCALE="15.13" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1562" TOTAL_2="1628" UNITS="" WEIGHT="100.0" Z="1.0419549331584148">
<NAME>Mean change in visual acuity at 1 year (number of letters)</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6876357084581297" CI_START="-8.08763570845813" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="3.22" ORDER="146" SD_1="15.6304" SD_2="12.0074" SE="2.7488442394631294" STUDY_ID="STD-Biswas-2011" TOTAL_1="50" TOTAL_2="54" WEIGHT="3.25018941239632" />
<CONT_DATA CI_END="1.547326406714129" CI_START="-4.16732640671413" EFFECT_SIZE="-1.3100000000000005" ESTIMABLE="YES" MEAN_1="5.09" MEAN_2="6.4" ORDER="157" SD_1="14.09" SD_2="12.17" SE="1.4578463835317157" STUDY_ID="STD-BRAMD-2016" TOTAL_1="161" TOTAL_2="166" WEIGHT="11.555411265012534" />
<CONT_DATA CI_END="1.0318915217241411" CI_START="-2.4524915217241414" EFFECT_SIZE="-0.7103000000000002" ESTIMABLE="YES" MEAN_1="6.9382" MEAN_2="7.6485" ORDER="142" SD_1="15.7698" SD_2="13.6229" SE="0.8888895589236974" STUDY_ID="STD-CATT-2011" TOTAL_1="536" TOTAL_2="569" WEIGHT="31.082312660994734" />
<CONT_DATA CI_END="4.925651177181426" CI_START="-1.145651177181426" EFFECT_SIZE="1.8900000000000001" ESTIMABLE="YES" MEAN_1="4.82" MEAN_2="2.93" ORDER="242" SD_1="14.85" SD_2="15.09" SE="1.5488300811271305" STUDY_ID="STD-GEFAL-2013" TOTAL_1="191" TOTAL_2="183" WEIGHT="10.237676092913368" />
<CONT_DATA CI_END="0.46720661704182387" CI_START="-3.8672066170418242" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="6.4" ORDER="143" SD_1="12.5" SD_2="12.8" SE="1.1057379799508935" STUDY_ID="STD-IVAN-2013" TOTAL_1="251" TOTAL_2="273" WEIGHT="20.086509779932474" />
<CONT_DATA CI_END="2.337904060667755" CI_START="-2.9379040606677527" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="8.2" ORDER="153" SD_1="13.4" SD_2="12.5" SE="1.3458941498288766" STUDY_ID="STD-LUCAS-2015" TOTAL_1="184" TOTAL_2="187" WEIGHT="13.55773446585185" />
<CONT_DATA CI_END="4.09855896561283" CI_START="-2.498558965612829" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.1" ORDER="147" SD_1="15.0756" SD_2="14.8702" SE="1.6829691727151324" STUDY_ID="STD-MANTA-2013" TOTAL_1="154" TOTAL_2="163" WEIGHT="8.67074896251108" />
<CONT_DATA CI_END="15.509313611142247" CI_START="-4.109313611142255" EFFECT_SIZE="5.699999999999996" ESTIMABLE="YES" MEAN_1="64.8" MEAN_2="59.1" ORDER="162" SD_1="17.0" SD_2="16.6" SE="5.004843807598948" STUDY_ID="STD-Scholler-2014" TOTAL_1="20" TOTAL_2="26" WEIGHT="0.9804554787307838" />
<CONT_DATA CI_END="13.965198507473065" CI_START="-11.565198507473063" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="6.3" ORDER="144" SD_1="15.3" SD_2="13.7" SE="6.512976058827265" STUDY_ID="STD-Subramanian-2010" TOTAL_1="15" TOTAL_2="7" WEIGHT="0.578961881656856" />
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1478064099921009" CI_END="0.5145368738723757" CI_START="-2.8221524404595426" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1538077832935834" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="0.7006406531568137" P_Q="1.0" P_Z="0.17526202668437257" Q="0.0" RANDOM="YES" SCALE="15.13" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="629" TOTAL_2="666" UNITS="" WEIGHT="99.99999999999999" Z="1.3554883222864325">
<NAME>Mean change in visual acuity at 2 years (number of letters)</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8160814048650553" CI_START="-3.7290814048650556" EFFECT_SIZE="-1.4565000000000001" ESTIMABLE="YES" MEAN_1="5.9505" MEAN_2="7.407" ORDER="145" SD_1="17.1539" SD_2="15.063" SE="1.1595016147188864" STUDY_ID="STD-CATT-2011" TOTAL_1="380" TOTAL_2="398" WEIGHT="53.8930362975755" />
<CONT_DATA CI_END="1.6569850455638568" CI_START="-3.2569850455638583" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.9" ORDER="143" SD_1="13.5" SD_2="15.0" SE="1.2535868337093141" STUDY_ID="STD-IVAN-2013" TOTAL_1="249" TOTAL_2="268" WEIGHT="46.10696370242449" />
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.27935161314551" CI_END="-1.6594940506437208" CI_START="-21.55380496975677" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.606649510200244" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" NO="9" P_CHI2="0.8092948568608052" P_Q="1.0" P_Z="0.022198930411029622" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1317" TOTAL_2="1376" UNITS="" WEIGHT="100.0" Z="2.2869467672103867">
<NAME>Reduction in central retinal thickness at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.670550183655692" CI_START="-25.97055018365569" EFFECT_SIZE="-1.1499999999999986" ESTIMABLE="YES" MEAN_1="26.44" MEAN_2="27.59" ORDER="308" SD_1="59.8589" SD_2="69.2121" SE="12.663778711974823" STUDY_ID="STD-Biswas-2011" TOTAL_1="50" TOTAL_2="54" WEIGHT="16.061089518192773" />
<CONT_DATA CI_END="19.7177027999178" CI_START="-33.7177027999178" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="131.0" MEAN_2="138.0" ORDER="158" SD_1="129.0" SD_2="117.0" SE="13.631731506631565" STUDY_ID="STD-BRAMD-2016" TOTAL_1="161" TOTAL_2="166" WEIGHT="13.861160159214677" />
<CONT_DATA CI_END="-2.6093462818698505" CI_START="-45.605253718130115" EFFECT_SIZE="-24.10729999999998" ESTIMABLE="YES" MEAN_1="157.9429" MEAN_2="182.0502" ORDER="309" SD_1="179.4211" SD_2="181.4304" SE="10.968545283333391" STUDY_ID="STD-CATT-2011" TOTAL_1="525" TOTAL_2="558" WEIGHT="21.409354019793966" />
<CONT_DATA CI_END="11.98759589448116" CI_START="-36.52759589448118" EFFECT_SIZE="-12.27000000000001" ESTIMABLE="YES" MEAN_1="94.96" MEAN_2="107.23" ORDER="306" SD_1="132.78" SD_2="103.25" SE="12.37655185800453" STUDY_ID="STD-GEFAL-2013" TOTAL_1="187" TOTAL_2="181" WEIGHT="16.81521005886053" />
<CONT_DATA CI_END="18.14439637911105" CI_START="-50.14439637911105" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="155.0" ORDER="307" SD_1="183.0" SD_2="182.0" SE="17.420930511191884" STUDY_ID="STD-IVAN-2013" TOTAL_1="210" TOTAL_2="230" WEIGHT="8.487092428062256" />
<CONT_DATA CI_END="12.578127197202924" CI_START="-28.578127197202924" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="112.0" MEAN_2="120.0" ORDER="154" SD_1="105.0" SD_2="97.0" SE="10.499237414320143" STUDY_ID="STD-LUCAS-2015" TOTAL_1="184" TOTAL_2="187" WEIGHT="23.3660938158758" />
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.002269821616075714" CI_END="9.03982884917226" CI_START="-33.831631773208336" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.395901462018038" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" NO="10" P_CHI2="0.9620010579043694" P_Q="1.0" P_Z="0.25704116941729294" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="592" TOTAL_2="607" UNITS="" WEIGHT="100.0" Z="1.1334123012724944">
<NAME>Reduction in central retinal thickness at 2 years</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.656753892915972" CI_START="-38.677353892915974" EFFECT_SIZE="-12.0103" ESTIMABLE="YES" MEAN_1="162.072" MEAN_2="174.0823" ORDER="310" SD_1="191.5445" SD_2="184.2627" SE="13.605889752700708" STUDY_ID="STD-CATT-2011" TOTAL_1="375" TOTAL_2="389" WEIGHT="64.61397980930184" />
<CONT_DATA CI_END="22.934825552005933" CI_START="-49.13482555200592" EFFECT_SIZE="-13.099999999999994" ESTIMABLE="YES" MEAN_1="133.8" MEAN_2="146.9" ORDER="311" SD_1="205.0" SD_2="177.4" SE="18.385452914565793" STUDY_ID="STD-IVAN-2013" TOTAL_1="217" TOTAL_2="218" WEIGHT="35.38602019069817" />
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="896" EVENTS_2="1000" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1310" TOTAL_2="1429" WEIGHT="0.0" Z="0.0">
<NAME>No problems in quality of life domain at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="155" EVENTS_2="173" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="286" WEIGHT="0.0" Z="0.0">
<NAME>Mobility</NAME>
<DICH_DATA CI_END="1.1221419654102176" CI_START="0.8524185055795086" EFFECT_SIZE="0.9780258571239465" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="173" LOG_CI_END="0.05004780424104403" LOG_CI_START="-0.06934713053945676" LOG_EFFECT_SIZE="-0.009649663149206383" ORDER="243" O_E="0.0" SE="0.07013317570452508" STUDY_ID="STD-IVAN-2013" TOTAL_1="262" TOTAL_2="286" VAR="0.004918662334401788" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="217" EVENTS_2="246" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="286" WEIGHT="0.0" Z="0.0">
<NAME>Self-care</NAME>
<DICH_DATA CI_END="1.0350958590889772" CI_START="0.8957734082463145" EFFECT_SIZE="0.962918140631788" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="246" LOG_CI_END="0.01498057118967046" LOG_CI_START="-0.047801834080774555" LOG_EFFECT_SIZE="-0.016410631445552045" ORDER="245" O_E="0.0" SE="0.036878695633777686" STUDY_ID="STD-IVAN-2013" TOTAL_1="262" TOTAL_2="286" VAR="0.0013600381916488136" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="178" EVENTS_2="199" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="286" WEIGHT="0.0" Z="0.0">
<NAME>Usual activities</NAME>
<DICH_DATA CI_END="1.093326314476681" CI_START="0.8719940759176302" EFFECT_SIZE="0.9764087613640723" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="199" LOG_CI_END="0.038749800948878366" LOG_CI_START="-0.059486465531908624" LOG_EFFECT_SIZE="-0.010368332291515113" ORDER="246" O_E="0.0" SE="0.057704469208175936" STUDY_ID="STD-IVAN-2013" TOTAL_1="262" TOTAL_2="286" VAR="0.003329805766597325" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="168" I2="0.0" ID="CMP-002.11.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="285" WEIGHT="0.0" Z="0.0">
<NAME>Pain/discomfort</NAME>
<DICH_DATA CI_END="1.1743960081105762" CI_START="0.8911856431400492" EFFECT_SIZE="1.0230370774263904" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="168" LOG_CI_END="0.06981456636414829" LOG_CI_START="-0.05003181852949925" LOG_EFFECT_SIZE="0.009891373917324508" ORDER="247" O_E="0.0" SE="0.07039835973570159" STUDY_ID="STD-IVAN-2013" TOTAL_1="262" TOTAL_2="285" VAR="0.004955929053477252" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="188" EVENTS_2="214" I2="0.0" ID="CMP-002.11.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="286" WEIGHT="0.0" Z="0.0">
<NAME>Anxiety/depression</NAME>
<DICH_DATA CI_END="1.0613634822057003" CI_START="0.8664699278151022" EFFECT_SIZE="0.9589783833915959" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="214" LOG_CI_END="0.02586414100074665" LOG_CI_START="-0.06224650555317353" LOG_EFFECT_SIZE="-0.018191182276213434" ORDER="244" O_E="0.0" SE="0.051756629940507407" STUDY_ID="STD-IVAN-2013" TOTAL_1="262" TOTAL_2="286" VAR="0.0026787487427986276" WEIGHT="0.0" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="916" EVENTS_2="994" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1235" TOTAL_2="1335" WEIGHT="0.0" Z="0.0">
<NAME>No problems in quality of life domain at 2 years</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ranibizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors bevacizumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="171" EVENTS_2="176" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="247" TOTAL_2="267" WEIGHT="0.0" Z="0.0">
<NAME>Mobility</NAME>
<DICH_DATA CI_END="1.1839263612059363" CI_START="0.9316886625835292" EFFECT_SIZE="1.0502622377622377" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="176" LOG_CI_END="0.07332469063311493" LOG_CI_START="-0.030729189267287967" LOG_EFFECT_SIZE="0.021297750682913483" ORDER="243" O_E="0.0" SE="0.06112176412850916" STUDY_ID="STD-IVAN-2013" TOTAL_1="247" TOTAL_2="267" VAR="0.0037358700501811085" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="218" EVENTS_2="247" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="247" TOTAL_2="267" WEIGHT="0.0" Z="0.0">
<NAME>Self-care</NAME>
<DICH_DATA CI_END="1.0098828170548928" CI_START="0.9013152392032896" EFFECT_SIZE="0.9540559589568752" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="247" LOG_CI_END="0.004270982833167072" LOG_CI_START="-0.045123285933469946" LOG_EFFECT_SIZE="-0.020426151550151404" ORDER="245" O_E="0.0" SE="0.02901443797909633" STUDY_ID="STD-IVAN-2013" TOTAL_1="247" TOTAL_2="267" VAR="8.418376112428274E-4" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="179" EVENTS_2="197" I2="0.0" ID="CMP-002.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="247" TOTAL_2="267" WEIGHT="0.0" Z="0.0">
<NAME>Usual activities</NAME>
<DICH_DATA CI_END="1.0909195731787988" CI_START="0.884320091046553" EFFECT_SIZE="0.9822026757639902" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="197" LOG_CI_END="0.03779273389525212" LOG_CI_START="-0.053390508048832656" LOG_EFFECT_SIZE="-0.007798887076790262" ORDER="246" O_E="0.0" SE="0.05356148768228252" STUDY_ID="STD-IVAN-2013" TOTAL_1="247" TOTAL_2="267" VAR="0.002868832962739302" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="145" EVENTS_2="154" I2="0.0" ID="CMP-002.12.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="247" TOTAL_2="267" WEIGHT="0.0" Z="0.0">
<NAME>Pain/discomfort</NAME>
<DICH_DATA CI_END="1.1785223401095775" CI_START="0.8789928847414863" EFFECT_SIZE="1.017797991482202" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="154" LOG_CI_END="0.07133781943934685" LOG_CI_START="-0.05601464043250422" LOG_EFFECT_SIZE="0.007661589503421295" ORDER="247" O_E="0.0" SE="0.07480746533356869" STUDY_ID="STD-IVAN-2013" TOTAL_1="247" TOTAL_2="267" VAR="0.005596156869633082" WEIGHT="0.0" />
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="203" EVENTS_2="220" I2="0.0" ID="CMP-002.12.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="247" TOTAL_2="267" WEIGHT="0.0" Z="0.0">
<NAME>Anxiety/depression</NAME>
<DICH_DATA CI_END="1.0808172231145492" CI_START="0.9204984758109651" EFFECT_SIZE="0.997442031652558" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="220" LOG_CI_END="0.033752256669056006" LOG_CI_START="-0.03597692627722371" LOG_EFFECT_SIZE="-0.0011123348040838307" ORDER="244" O_E="0.0" SE="0.04095926722766703" STUDY_ID="STD-IVAN-2013" TOTAL_1="247" TOTAL_2="267" VAR="0.0016776615718274387" WEIGHT="0.0" />
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Loss of fewer than 30 letters visual acuity at 1 year</NAME>
<GROUP_LABEL_1>Bevacizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Ranibizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bevacizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ranibizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.534440178107545" CI_START="0.08651386907386269" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2908009696410434" LOG_CI_START="-1.0629142650273702" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="161" O_E="0.0" SE="1.382583979922544" STUDY_ID="STD-Scholler-2014" TOTAL_1="20" TOTAL_2="26" VAR="1.9115384615384614" WEIGHT="0.0" />
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES />
<FEEDBACK />
<APPENDICES />
<EXTENSIONS />
</COCHRANE_REVIEW>
